CA2529406A1 - New use i - Google Patents
New use i Download PDFInfo
- Publication number
- CA2529406A1 CA2529406A1 CA002529406A CA2529406A CA2529406A1 CA 2529406 A1 CA2529406 A1 CA 2529406A1 CA 002529406 A CA002529406 A CA 002529406A CA 2529406 A CA2529406 A CA 2529406A CA 2529406 A1 CA2529406 A1 CA 2529406A1
- Authority
- CA
- Canada
- Prior art keywords
- thiazol
- ethyl
- amino
- sulfonyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000029663 wound healing Effects 0.000 claims abstract description 36
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000003112 inhibitor Substances 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims abstract description 6
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- -1 di-substituted, amide Chemical class 0.000 claims description 238
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 117
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 102
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 91
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 206010052428 Wound Diseases 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 208000027418 Wounds and injury Diseases 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 239000003862 glucocorticoid Substances 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 12
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 10
- 230000001771 impaired effect Effects 0.000 claims description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 230000003111 delayed effect Effects 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 6
- 101710088194 Dehydrogenase Proteins 0.000 claims description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 239000004305 biphenyl Substances 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- 208000000558 Varicose Ulcer Diseases 0.000 claims description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 239000000651 prodrug Chemical group 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- NZTTXVUMWMHNPQ-UHFFFAOYSA-N 2,4,6-trichloro-n-[4-(2-morpholin-4-ylethyl)-1,3-thiazol-2-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.ClC1=CC(Cl)=CC(Cl)=C1S(=O)(=O)NC1=NC(CCN2CCOCC2)=CS1 NZTTXVUMWMHNPQ-UHFFFAOYSA-N 0.000 claims description 2
- AGYLTFIWEUGKRP-UHFFFAOYSA-N 2,4-dichloro-6-methyl-n-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C1CN(C)CCN1C(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2C)Cl)=N1 AGYLTFIWEUGKRP-UHFFFAOYSA-N 0.000 claims description 2
- QUTPYRLKSYVDGL-UHFFFAOYSA-N 2,4-dichloro-n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 QUTPYRLKSYVDGL-UHFFFAOYSA-N 0.000 claims description 2
- AJWZZHZNTINJCH-UHFFFAOYSA-N 2-[2-[(2-chlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetic acid Chemical compound OC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 AJWZZHZNTINJCH-UHFFFAOYSA-N 0.000 claims description 2
- QOLLTXJGTDTYQY-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n,n-dipropylacetamide Chemical compound CCCN(CCC)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 QOLLTXJGTDTYQY-UHFFFAOYSA-N 0.000 claims description 2
- VISGQGQJQWSXHJ-UHFFFAOYSA-N 2-[2-[(4-acetamidophenyl)sulfonylamino]-4-thiazolyl]acetic acid ethyl ester Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(NC(C)=O)=CC=2)=N1 VISGQGQJQWSXHJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- SPPUGWFMZNHQCI-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(2-oxo-2-piperidin-1-ylethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CC(=O)N2CCCCC2)=CS1 SPPUGWFMZNHQCI-UHFFFAOYSA-N 0.000 claims description 2
- LRSHRBXCWRJSCQ-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(2-oxopentyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CCCC(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 LRSHRBXCWRJSCQ-UHFFFAOYSA-N 0.000 claims description 2
- RJBYZNYPFAZOTP-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(2-propan-2-yloxyethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC(C)OCCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 RJBYZNYPFAZOTP-UHFFFAOYSA-N 0.000 claims description 2
- GQMBSMSODYSGSD-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(morpholin-4-ylmethyl)-1,3-thiazol-2-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CN2CCOCC2)=CS1 GQMBSMSODYSGSD-UHFFFAOYSA-N 0.000 claims description 2
- FCZLQYWUZTVEES-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[(3-oxomorpholin-4-yl)methyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CN2C(COCC2)=O)=CS1 FCZLQYWUZTVEES-UHFFFAOYSA-N 0.000 claims description 2
- PHBNCWNLQYXOBD-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN2C(CCC2)=O)=CS1 PHBNCWNLQYXOBD-UHFFFAOYSA-N 0.000 claims description 2
- UZWQRKFUNIGEEO-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(trifluoromethylsulfonylamino)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCNS(=O)(=O)C(F)(F)F)=CS1 UZWQRKFUNIGEEO-UHFFFAOYSA-N 0.000 claims description 2
- WPQLIXHVJMZDCD-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[3-(3-oxomorpholin-4-yl)propyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCCN2C(COCC2)=O)=CS1 WPQLIXHVJMZDCD-UHFFFAOYSA-N 0.000 claims description 2
- XNIJTLZWWZHATQ-UHFFFAOYSA-N 3-chloro-n-[4-(2-chloroethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCCl)=CS1 XNIJTLZWWZHATQ-UHFFFAOYSA-N 0.000 claims description 2
- PMDHDRBKLSNVTO-UHFFFAOYSA-N 3-chloro-n-[4-(2-ethoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound CCOCCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 PMDHDRBKLSNVTO-UHFFFAOYSA-N 0.000 claims description 2
- PSIMSLBVQXNOEQ-UHFFFAOYSA-N 3-chloro-n-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCO)=CS1 PSIMSLBVQXNOEQ-UHFFFAOYSA-N 0.000 claims description 2
- UQAMHSFHVDZYEN-UHFFFAOYSA-N 3-chloro-n-[4-(2-imidazol-1-ylethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN2C=NC=C2)=CS1 UQAMHSFHVDZYEN-UHFFFAOYSA-N 0.000 claims description 2
- MQNNPMUEUFLKRU-UHFFFAOYSA-N 3-chloro-n-[4-[2-(2-fluoroethoxy)ethyl]-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCOCCF)=CS1 MQNNPMUEUFLKRU-UHFFFAOYSA-N 0.000 claims description 2
- GDULMDVSHSQBBG-UHFFFAOYSA-N 3-chloro-n-[4-[2-(diethylamino)ethyl]-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.CCN(CC)CCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 GDULMDVSHSQBBG-UHFFFAOYSA-N 0.000 claims description 2
- GVEMPLKGNIFWOE-UHFFFAOYSA-N 3-chloro-n-[4-[2-(ethylamino)ethyl]-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound CCNCCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 GVEMPLKGNIFWOE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- ZHLZAFKVZBBSST-UHFFFAOYSA-N 4-(1-benzofuran-2-yl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C=1SC(NS(=O)(=O)C=2C=CC(=CC=2)C=2OC3=CC=CC=C3C=2)=NC=1CC(=O)N1CCOCC1 ZHLZAFKVZBBSST-UHFFFAOYSA-N 0.000 claims description 2
- IDDLDQUYMRMWCT-UHFFFAOYSA-N 4-(4-methylsulfanylphenyl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C1=CC(SC)=CC=C1C1=CC=C(S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)C=C1 IDDLDQUYMRMWCT-UHFFFAOYSA-N 0.000 claims description 2
- ICPHOALRDGJDLO-UHFFFAOYSA-N 4-(benzylamino)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C1COCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1NCC1=CC=CC=C1 ICPHOALRDGJDLO-UHFFFAOYSA-N 0.000 claims description 2
- ISYTZMQFESIBML-UHFFFAOYSA-N 4-[3,5-bis(trifluoromethyl)phenyl]-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)=C1 ISYTZMQFESIBML-UHFFFAOYSA-N 0.000 claims description 2
- APQOEJCRFPFNBZ-UHFFFAOYSA-N 4-[4-[[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]sulfamoyl]phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)C=C1 APQOEJCRFPFNBZ-UHFFFAOYSA-N 0.000 claims description 2
- NOLMXNHBTMCQLS-UHFFFAOYSA-N 4-chloro-n-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound OCCC1=CSC(NS(=O)(=O)C=2C=CC(Cl)=CC=2)=N1 NOLMXNHBTMCQLS-UHFFFAOYSA-N 0.000 claims description 2
- QFDBISKHFLCXAV-UHFFFAOYSA-N 4-morpholin-4-yl-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C1COCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1N1CCOCC1 QFDBISKHFLCXAV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 150000001204 N-oxides Chemical group 0.000 claims description 2
- WLYPBMBWKYALCG-UHFFFAOYSA-N [2,4-bis(trifluoromethyl)phenyl]boronic acid Chemical group OB(O)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F WLYPBMBWKYALCG-UHFFFAOYSA-N 0.000 claims description 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000001769 aryl amino group Chemical group 0.000 claims description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
- 125000005110 aryl thio group Chemical group 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- OBFRWCVXUAAEQG-UHFFFAOYSA-N ethyl 2-[2-(naphthalen-1-ylsulfonylamino)-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=N1 OBFRWCVXUAAEQG-UHFFFAOYSA-N 0.000 claims description 2
- AYEZJMCEEUOZBO-UHFFFAOYSA-N ethyl 2-[2-[(2,3,4-trichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C(Cl)=CC=2)Cl)=N1 AYEZJMCEEUOZBO-UHFFFAOYSA-N 0.000 claims description 2
- FFIWDZOIZSYFCK-UHFFFAOYSA-N ethyl 2-[2-[(2,3,4-trifluorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(F)C(F)=CC=2)F)=N1 FFIWDZOIZSYFCK-UHFFFAOYSA-N 0.000 claims description 2
- CBVGFYLRKFMWIY-UHFFFAOYSA-N ethyl 2-[2-[(2,3-dichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)Cl)=N1 CBVGFYLRKFMWIY-UHFFFAOYSA-N 0.000 claims description 2
- DFPIHKZQUYAUSJ-UHFFFAOYSA-N ethyl 2-[2-[(2,4,5-trichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 DFPIHKZQUYAUSJ-UHFFFAOYSA-N 0.000 claims description 2
- DOCGWETVZQBVQM-UHFFFAOYSA-N ethyl 2-[2-[(2,4-dichloro-5-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=C(C)C=2)Cl)=N1 DOCGWETVZQBVQM-UHFFFAOYSA-N 0.000 claims description 2
- LFHRKMQLRBNRKC-UHFFFAOYSA-N ethyl 2-[2-[(2,4-difluorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(F)=CC=2)F)=N1 LFHRKMQLRBNRKC-UHFFFAOYSA-N 0.000 claims description 2
- KACQGQGBDKICBL-UHFFFAOYSA-N ethyl 2-[2-[(2,5-dichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=C(Cl)C=2)Cl)=N1 KACQGQGBDKICBL-UHFFFAOYSA-N 0.000 claims description 2
- FUOFZFZFISSASM-UHFFFAOYSA-N ethyl 2-[2-[(2,6-dichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=CC=2Cl)Cl)=N1 FUOFZFZFISSASM-UHFFFAOYSA-N 0.000 claims description 2
- IQHJPEZHJFMMKA-UHFFFAOYSA-N ethyl 2-[2-[(2-bromophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=CC=2)Br)=N1 IQHJPEZHJFMMKA-UHFFFAOYSA-N 0.000 claims description 2
- JDBWRECUZVWGNO-UHFFFAOYSA-N ethyl 2-[2-[(2-chlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 JDBWRECUZVWGNO-UHFFFAOYSA-N 0.000 claims description 2
- HAGXVJTVTTUNAP-UHFFFAOYSA-N ethyl 2-[2-[(2-cyanophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=CC=2)C#N)=N1 HAGXVJTVTTUNAP-UHFFFAOYSA-N 0.000 claims description 2
- PMRYJIFBBGSVKP-UHFFFAOYSA-N ethyl 2-[2-[(2-methoxy-4-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(C)=CC=2)OC)=N1 PMRYJIFBBGSVKP-UHFFFAOYSA-N 0.000 claims description 2
- LNAGTOPKTFQIIS-UHFFFAOYSA-N ethyl 2-[2-[(2-methylsulfonylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=CC=2)S(C)(=O)=O)=N1 LNAGTOPKTFQIIS-UHFFFAOYSA-N 0.000 claims description 2
- WYLIDXHKCNSRSG-UHFFFAOYSA-N ethyl 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 WYLIDXHKCNSRSG-UHFFFAOYSA-N 0.000 claims description 2
- ANVGCTSGCSBOTQ-UHFFFAOYSA-N ethyl 2-[2-[(3-chloro-4-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(Cl)C(C)=CC=2)=N1 ANVGCTSGCSBOTQ-UHFFFAOYSA-N 0.000 claims description 2
- YTRIEVDHWCSHLN-UHFFFAOYSA-N ethyl 2-[2-[(3-chlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(Cl)C=CC=2)=N1 YTRIEVDHWCSHLN-UHFFFAOYSA-N 0.000 claims description 2
- WDZSIANQAZTVEH-UHFFFAOYSA-N ethyl 2-[2-[(3-cyanophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(C=CC=2)C#N)=N1 WDZSIANQAZTVEH-UHFFFAOYSA-N 0.000 claims description 2
- BOFWWAXNVWTGKH-UHFFFAOYSA-N ethyl 2-[2-[(3-fluorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(F)C=CC=2)=N1 BOFWWAXNVWTGKH-UHFFFAOYSA-N 0.000 claims description 2
- PZARFSJHMREGLA-UHFFFAOYSA-N ethyl 2-[2-[(3-methoxyphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(OC)C=CC=2)=N1 PZARFSJHMREGLA-UHFFFAOYSA-N 0.000 claims description 2
- WZQBUAOAZRGEBW-UHFFFAOYSA-N ethyl 2-[2-[(3-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(C)C=CC=2)=N1 WZQBUAOAZRGEBW-UHFFFAOYSA-N 0.000 claims description 2
- JWPFFPNIEBVQBS-UHFFFAOYSA-N ethyl 2-[2-[(4,5-dichlorothiophen-2-yl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2SC(Cl)=C(Cl)C=2)=N1 JWPFFPNIEBVQBS-UHFFFAOYSA-N 0.000 claims description 2
- GTGYIXMGPVAEAW-UHFFFAOYSA-N ethyl 2-[2-[(4-bromo-2,5-difluorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Br)=C(F)C=2)F)=N1 GTGYIXMGPVAEAW-UHFFFAOYSA-N 0.000 claims description 2
- XQETZYRGNIDJBQ-UHFFFAOYSA-N ethyl 2-[2-[(4-bromo-2-fluorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Br)=CC=2)F)=N1 XQETZYRGNIDJBQ-UHFFFAOYSA-N 0.000 claims description 2
- GJLYEXVGTDRIDB-UHFFFAOYSA-N ethyl 2-[2-[(4-bromo-5-chlorothiophen-2-yl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2SC(Cl)=C(Br)C=2)=N1 GJLYEXVGTDRIDB-UHFFFAOYSA-N 0.000 claims description 2
- IITATKCUYSUFMF-UHFFFAOYSA-N ethyl 2-[2-[(4-chlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(Cl)=CC=2)=N1 IITATKCUYSUFMF-UHFFFAOYSA-N 0.000 claims description 2
- IUMBUSOAXLMIQO-UHFFFAOYSA-N ethyl 2-[2-[(4-iodophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(I)=CC=2)=N1 IUMBUSOAXLMIQO-UHFFFAOYSA-N 0.000 claims description 2
- UZBKVHNVGKVIBK-UHFFFAOYSA-N ethyl 2-[2-[(4-methoxyphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(OC)=CC=2)=N1 UZBKVHNVGKVIBK-UHFFFAOYSA-N 0.000 claims description 2
- GGFUIBCPKURKMT-UHFFFAOYSA-N ethyl 2-[2-[(4-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(C)=CC=2)=N1 GGFUIBCPKURKMT-UHFFFAOYSA-N 0.000 claims description 2
- OGXYMEROVHKCKW-UHFFFAOYSA-N ethyl 2-[2-[(4-methylsulfonylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)S(C)(=O)=O)=N1 OGXYMEROVHKCKW-UHFFFAOYSA-N 0.000 claims description 2
- UWYFMDJTWUHYCH-UHFFFAOYSA-N ethyl 2-[2-[(4-nitrophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)[N+]([O-])=O)=N1 UWYFMDJTWUHYCH-UHFFFAOYSA-N 0.000 claims description 2
- HTGLZCFZWSAEEN-UHFFFAOYSA-N ethyl 2-[2-[(4-propan-2-ylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)C(C)C)=N1 HTGLZCFZWSAEEN-UHFFFAOYSA-N 0.000 claims description 2
- LVTJYYCKVHDIKX-UHFFFAOYSA-N ethyl 2-[2-[(5-chloro-1,3-dimethylpyrazol-4-yl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C2=C(N(C)N=C2C)Cl)=N1 LVTJYYCKVHDIKX-UHFFFAOYSA-N 0.000 claims description 2
- HKEFYAKHKFYMMG-UHFFFAOYSA-N ethyl 2-[2-[(5-fluoro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=C(F)C=2)C)=N1 HKEFYAKHKFYMMG-UHFFFAOYSA-N 0.000 claims description 2
- HMGOOODTJVJVDK-CMDGGOBGSA-N ethyl 2-[2-[[(e)-2-phenylethenyl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)\C=C\C=2C=CC=CC=2)=N1 HMGOOODTJVJVDK-CMDGGOBGSA-N 0.000 claims description 2
- LSUOHCBWXCYLMG-UHFFFAOYSA-N ethyl 2-[2-[[4-(benzenesulfonyl)thiophen-2-yl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2SC=C(C=2)S(=O)(=O)C=2C=CC=CC=2)=N1 LSUOHCBWXCYLMG-UHFFFAOYSA-N 0.000 claims description 2
- AXHPKOPJFWOGEG-UHFFFAOYSA-N ethyl 2-[2-[[4-(trifluoromethoxy)phenyl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(OC(F)(F)F)=CC=2)=N1 AXHPKOPJFWOGEG-UHFFFAOYSA-N 0.000 claims description 2
- IGKYRCNENBYGMB-UHFFFAOYSA-N ethyl 2-[2-[[5-(2-methylsulfanylpyrimidin-4-yl)thiophen-2-yl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2SC(=CC=2)C=2N=C(SC)N=CC=2)=N1 IGKYRCNENBYGMB-UHFFFAOYSA-N 0.000 claims description 2
- MZTOQUINLWUTBG-UHFFFAOYSA-N ethyl 2-[2-[[5-(benzamidomethyl)thiophen-2-yl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2SC(CNC(=O)C=3C=CC=CC=3)=CC=2)=N1 MZTOQUINLWUTBG-UHFFFAOYSA-N 0.000 claims description 2
- JPINMSJPGIZMAC-UHFFFAOYSA-N ethyl 2-[2-[[5-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophen-2-yl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2SC(=CC=2)C2=NN(C)C(=C2)C(F)(F)F)=N1 JPINMSJPGIZMAC-UHFFFAOYSA-N 0.000 claims description 2
- IEGXMLXVLNHQQR-UHFFFAOYSA-N ethyl 3-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]propanoate Chemical compound CCOC(=O)CCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 IEGXMLXVLNHQQR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 2
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- POQSMNSPMDVTHU-UHFFFAOYSA-N methyl 2-[5-methyl-2-[(4-propylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NC(CC(=O)OC)=C(C)S1 POQSMNSPMDVTHU-UHFFFAOYSA-N 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- KCIZIKWZFCENMB-UHFFFAOYSA-N n,n-di(propan-2-yl)-2-[2-[(2,4,6-trichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetamide Chemical compound CC(C)N(C(C)C)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2Cl)Cl)=N1 KCIZIKWZFCENMB-UHFFFAOYSA-N 0.000 claims description 2
- VYJPKJQHXPFNGR-UHFFFAOYSA-N n,n-diethyl-2-[2-[(4-propylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NC(CC(=O)N(CC)CC)=CS1 VYJPKJQHXPFNGR-UHFFFAOYSA-N 0.000 claims description 2
- IERVETIQARVCNC-UHFFFAOYSA-N n-[2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl]acetamide Chemical compound CC(=O)NCCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 IERVETIQARVCNC-UHFFFAOYSA-N 0.000 claims description 2
- IABWJYRLNHRIAD-UHFFFAOYSA-N n-[3-[4-[[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]sulfamoyl]phenyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)=C1 IABWJYRLNHRIAD-UHFFFAOYSA-N 0.000 claims description 2
- AWIAVOKXWLWHRF-UHFFFAOYSA-N n-[4-(2-aminoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN)=CS1 AWIAVOKXWLWHRF-UHFFFAOYSA-N 0.000 claims description 2
- HDGAICTWOOQDHI-UHFFFAOYSA-N n-[4-(2-azidoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN=[N+]=[N-])=CS1 HDGAICTWOOQDHI-UHFFFAOYSA-N 0.000 claims description 2
- DIVHULOBFPKRPY-UHFFFAOYSA-N n-[4-(2-bromoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCBr)=CS1 DIVHULOBFPKRPY-UHFFFAOYSA-N 0.000 claims description 2
- HGKDCXUVCCYZOK-UHFFFAOYSA-N n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]-4-(3-nitrophenyl)benzenesulfonamide Chemical compound [O-][N+](=O)C1=CC=CC(C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)=C1 HGKDCXUVCCYZOK-UHFFFAOYSA-N 0.000 claims description 2
- OSKLWZDEGFSCDY-UHFFFAOYSA-N n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]-4-(pyridin-3-ylmethylamino)benzenesulfonamide Chemical compound C1COCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1NCC1=CC=CN=C1 OSKLWZDEGFSCDY-UHFFFAOYSA-N 0.000 claims description 2
- SNKHZWZVCPVFIJ-UHFFFAOYSA-N n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]-4-(thiophen-2-ylmethylamino)benzenesulfonamide Chemical compound C1COCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1NCC1=CC=CS1 SNKHZWZVCPVFIJ-UHFFFAOYSA-N 0.000 claims description 2
- YLRZGZIHQQPNCD-UHFFFAOYSA-N n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]-4-thiophen-2-ylbenzenesulfonamide Chemical compound C1COCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1C1=CC=CS1 YLRZGZIHQQPNCD-UHFFFAOYSA-N 0.000 claims description 2
- YVKCRYGFPBTSGK-UHFFFAOYSA-N n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]-4-thiophen-3-ylbenzenesulfonamide Chemical compound C1COCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1C=1C=CSC=1 YVKCRYGFPBTSGK-UHFFFAOYSA-N 0.000 claims description 2
- SMNHFSUWUBCFBM-UHFFFAOYSA-N n-benzyl-2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-ethylacetamide Chemical compound C=1SC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=NC=1CC(=O)N(CC)CC1=CC=CC=C1 SMNHFSUWUBCFBM-UHFFFAOYSA-N 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims 1
- FEYIHTAVPXMQEK-UHFFFAOYSA-N 2,4,6-trichloro-n-[4-(2-oxo-2-thiomorpholin-4-ylethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC(Cl)=C1S(=O)(=O)NC1=NC(CC(=O)N2CCSCC2)=CS1 FEYIHTAVPXMQEK-UHFFFAOYSA-N 0.000 claims 1
- CGPRKKGTHPOISW-UHFFFAOYSA-N 2,4,6-trichloro-n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC(Cl)=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 CGPRKKGTHPOISW-UHFFFAOYSA-N 0.000 claims 1
- UDSFXWYSYFILMF-UHFFFAOYSA-N 2,4,6-trichloro-n-[5-methyl-4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound N=1C(CC(=O)N2CCOCC2)=C(C)SC=1NS(=O)(=O)C1=C(Cl)C=C(Cl)C=C1Cl UDSFXWYSYFILMF-UHFFFAOYSA-N 0.000 claims 1
- NLRRMVIFHMHEGQ-UHFFFAOYSA-N 2,4-dichloro-6-methyl-n-[4-(2-morpholin-4-ylethyl)-1,3-thiazol-2-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.CC1=CC(Cl)=CC(Cl)=C1S(=O)(=O)NC1=NC(CCN2CCOCC2)=CS1 NLRRMVIFHMHEGQ-UHFFFAOYSA-N 0.000 claims 1
- OHWFDVUOIJVLGT-UHFFFAOYSA-N 2,4-dichloro-6-methyl-n-[4-(2-oxo-2-thiomorpholin-4-ylethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=CC(Cl)=CC(Cl)=C1S(=O)(=O)NC1=NC(CC(=O)N2CCSCC2)=CS1 OHWFDVUOIJVLGT-UHFFFAOYSA-N 0.000 claims 1
- OCKUKOAKTSTSHL-UHFFFAOYSA-N 2,4-dichloro-6-methyl-n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=CC(Cl)=CC(Cl)=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 OCKUKOAKTSTSHL-UHFFFAOYSA-N 0.000 claims 1
- VCZAXMJNUKICQT-UHFFFAOYSA-N 2,4-dichloro-6-methyl-n-[5-methyl-4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound N=1C(CC(=O)N2CCOCC2)=C(C)SC=1NS(=O)(=O)C1=C(C)C=C(Cl)C=C1Cl VCZAXMJNUKICQT-UHFFFAOYSA-N 0.000 claims 1
- DOTRAHDBXAHCSW-UHFFFAOYSA-N 2,4-dichloro-n-[4-(2-morpholin-4-ylethyl)-1,3-thiazol-2-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.ClC1=CC(Cl)=CC=C1S(=O)(=O)NC1=NC(CCN2CCOCC2)=CS1 DOTRAHDBXAHCSW-UHFFFAOYSA-N 0.000 claims 1
- WVSCPCGKOUHZLV-UHFFFAOYSA-N 2,4-dichloro-n-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C1CN(C)CCN1C(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2)Cl)=N1 WVSCPCGKOUHZLV-UHFFFAOYSA-N 0.000 claims 1
- JMBAHDKUIHPACC-UHFFFAOYSA-N 2-[2-(benzenesulfonamido)-1,3-thiazol-4-yl]-n-(cyclohexylmethyl)acetamide Chemical compound C1CCCCC1CNC(=O)CC(N=1)=CSC=1NS(=O)(=O)C1=CC=CC=C1 JMBAHDKUIHPACC-UHFFFAOYSA-N 0.000 claims 1
- JLAXYEKZOBHMQD-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylsulfonylamino)-1,3-thiazol-4-yl]-n-propan-2-ylacetamide Chemical compound CC(C)NC(=O)CC1=CSC(NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=N1 JLAXYEKZOBHMQD-UHFFFAOYSA-N 0.000 claims 1
- JZBMRTMNGYNDHZ-UHFFFAOYSA-N 2-[2-[(2,4-dichloro-6-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n,n-di(propan-2-yl)acetamide Chemical compound CC(C)N(C(C)C)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2C)Cl)=N1 JZBMRTMNGYNDHZ-UHFFFAOYSA-N 0.000 claims 1
- WSKHSWHWEKUKCK-UHFFFAOYSA-N 2-[2-[(2,4-dichloro-6-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n,n-diethylacetamide Chemical compound CCN(CC)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2C)Cl)=N1 WSKHSWHWEKUKCK-UHFFFAOYSA-N 0.000 claims 1
- RBJALPGWPKFZJQ-UHFFFAOYSA-N 2-[2-[(2,4-dichloro-6-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-ethyl-n-methylacetamide Chemical compound CCN(C)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2C)Cl)=N1 RBJALPGWPKFZJQ-UHFFFAOYSA-N 0.000 claims 1
- JBKXGULGNQEDPS-UHFFFAOYSA-N 2-[2-[(2,4-difluorophenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-ethylacetamide Chemical compound CCNC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(F)=CC=2)F)=N1 JBKXGULGNQEDPS-UHFFFAOYSA-N 0.000 claims 1
- WYWISWQMNVHCCM-UHFFFAOYSA-N 2-[2-[(2,5-dichlorothiophen-3-yl)sulfonylamino]-1,3-thiazol-4-yl]-n-methylacetamide Chemical compound CNC(=O)CC1=CSC(NS(=O)(=O)C2=C(SC(Cl)=C2)Cl)=N1 WYWISWQMNVHCCM-UHFFFAOYSA-N 0.000 claims 1
- OQUSPHXWLUOJKV-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n,n-di(propan-2-yl)acetamide Chemical compound CC(C)N(C(C)C)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 OQUSPHXWLUOJKV-UHFFFAOYSA-N 0.000 claims 1
- PNFMZAHWOASGJC-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n,n-diethylacetamide Chemical compound CCN(CC)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 PNFMZAHWOASGJC-UHFFFAOYSA-N 0.000 claims 1
- NKUJXDCGXSYHFM-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 NKUJXDCGXSYHFM-UHFFFAOYSA-N 0.000 claims 1
- NSBLVGFETONCLJ-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-ethyl-n-methylacetamide Chemical compound CCN(C)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 NSBLVGFETONCLJ-UHFFFAOYSA-N 0.000 claims 1
- MWLVRQCUVOUIBF-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-ethylacetamide Chemical compound CCNC(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 MWLVRQCUVOUIBF-UHFFFAOYSA-N 0.000 claims 1
- RVGOYEWLPWEFCI-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-methoxy-n-methylacetamide Chemical compound CON(C)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 RVGOYEWLPWEFCI-UHFFFAOYSA-N 0.000 claims 1
- RPZCXMXPXXVKKM-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-methyl-n-phenylacetamide Chemical compound C=1C=CC=CC=1N(C)C(=O)CC(N=1)=CSC=1NS(=O)(=O)C1=CC=CC(Cl)=C1C RPZCXMXPXXVKKM-UHFFFAOYSA-N 0.000 claims 1
- NSIMZMOFHFLYCX-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-methyl-n-propan-2-ylacetamide Chemical compound CC(C)N(C)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 NSIMZMOFHFLYCX-UHFFFAOYSA-N 0.000 claims 1
- HCVDPOLLLJHUPC-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-methylacetamide Chemical compound CNC(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 HCVDPOLLLJHUPC-UHFFFAOYSA-N 0.000 claims 1
- ZFZSPBPBECULLJ-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-phenylacetamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CC(=O)NC=2C=CC=CC=2)=CS1 ZFZSPBPBECULLJ-UHFFFAOYSA-N 0.000 claims 1
- PBNMKZXABHYGGL-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CC(N)=O)=CS1 PBNMKZXABHYGGL-UHFFFAOYSA-N 0.000 claims 1
- WBXQHDLZILRZTA-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl 2-methylpropanoate Chemical compound CC(C)C(=O)OCCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 WBXQHDLZILRZTA-UHFFFAOYSA-N 0.000 claims 1
- YJJNYKUVWNSKQE-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl acetate Chemical compound CC(=O)OCCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 YJJNYKUVWNSKQE-UHFFFAOYSA-N 0.000 claims 1
- HBSWMTRBCJGKNK-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl benzoate Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCOC(=O)C=2C=CC=CC=2)=CS1 HBSWMTRBCJGKNK-UHFFFAOYSA-N 0.000 claims 1
- VYZWVMVWGHXNGP-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl methanesulfonate Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCOS(C)(=O)=O)=CS1 VYZWVMVWGHXNGP-UHFFFAOYSA-N 0.000 claims 1
- CFFAUMQTHWNDOK-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl morpholine-4-carboxylate Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCOC(=O)N2CCOCC2)=CS1 CFFAUMQTHWNDOK-UHFFFAOYSA-N 0.000 claims 1
- NUSJTMYRJVRWGH-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl n-ethylcarbamate Chemical compound CCNC(=O)OCCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 NUSJTMYRJVRWGH-UHFFFAOYSA-N 0.000 claims 1
- VKMTYZOUAYGZLK-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl propanoate Chemical compound CCC(=O)OCCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 VKMTYZOUAYGZLK-UHFFFAOYSA-N 0.000 claims 1
- KIYPUUWMSLECQJ-UHFFFAOYSA-N 2-[2-[(4-chlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-(furan-2-ylmethyl)acetamide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC1=NC(CC(=O)NCC=2OC=CC=2)=CS1 KIYPUUWMSLECQJ-UHFFFAOYSA-N 0.000 claims 1
- OEUIPTZTKZPHFU-UHFFFAOYSA-N 2-[2-[(4-phenylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n,n-di(propan-2-yl)acetamide Chemical compound CC(C)N(C(C)C)C(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 OEUIPTZTKZPHFU-UHFFFAOYSA-N 0.000 claims 1
- LUYHJLGAOMXVJE-UHFFFAOYSA-N 2-chloro-5-[[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl]sulfamoyl]-4-fluorobenzoic acid Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=C(C(O)=O)C=2)F)=N1 LUYHJLGAOMXVJE-UHFFFAOYSA-N 0.000 claims 1
- YWCBGZLJKFQWCX-UHFFFAOYSA-N 2-methyl-n-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]-4-(trifluoromethoxy)benzenesulfonamide Chemical compound C1CN(C)CCN1C(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(OC(F)(F)F)=CC=2)C)=N1 YWCBGZLJKFQWCX-UHFFFAOYSA-N 0.000 claims 1
- RQENMSXJKNRXFR-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(2-morpholin-4-ylethyl)-1,3-thiazol-2-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN2CCOCC2)=CS1 RQENMSXJKNRXFR-UHFFFAOYSA-N 0.000 claims 1
- SBMGFUZZILGLEQ-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(2-oxo-2-pyrrolidin-1-ylethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CC(=O)N2CCCC2)=CS1 SBMGFUZZILGLEQ-UHFFFAOYSA-N 0.000 claims 1
- PNOHBAWJVWEEEW-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(2-oxo-2-thiomorpholin-4-ylethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CC(=O)N2CCSCC2)=CS1 PNOHBAWJVWEEEW-UHFFFAOYSA-N 0.000 claims 1
- PCURMNYHJKIXIK-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(2-phenylmethoxyethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCOCC=2C=CC=CC=2)=CS1 PCURMNYHJKIXIK-UHFFFAOYSA-N 0.000 claims 1
- FEBDOOGGNQMLEA-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(2-pyridin-2-ylsulfanylethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCSC=2N=CC=CC=2)=CS1 FEBDOOGGNQMLEA-UHFFFAOYSA-N 0.000 claims 1
- GOOHJWXSYSIJCN-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(2-pyridin-3-yloxyethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCOC=2C=NC=CC=2)=CS1 GOOHJWXSYSIJCN-UHFFFAOYSA-N 0.000 claims 1
- SKFUKFDKZSDFRR-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound O1C(C)=NN=C1CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 SKFUKFDKZSDFRR-UHFFFAOYSA-N 0.000 claims 1
- UZLWJPBUKCZYIM-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(2,2,2-trifluoroethoxy)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCOCC(F)(F)F)=CS1 UZLWJPBUKCZYIM-UHFFFAOYSA-N 0.000 claims 1
- WZFZJEPHYDDFCT-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 WZFZJEPHYDDFCT-UHFFFAOYSA-N 0.000 claims 1
- OKCFHSSPFHFJMD-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(4-methyl-2-oxopiperazin-1-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound O=C1CN(C)CCN1CCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 OKCFHSSPFHFJMD-UHFFFAOYSA-N 0.000 claims 1
- WZFHKKLPBJCDRS-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(4-methylpiperazin-1-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1CCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 WZFHKKLPBJCDRS-UHFFFAOYSA-N 0.000 claims 1
- VQQOVTXLJDVTLF-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(4-methylpiperazin-4-ium-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide;chloride Chemical compound Cl.C1CN(C)CCN1C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 VQQOVTXLJDVTLF-UHFFFAOYSA-N 0.000 claims 1
- DWUNSAFRDBHZOU-STQMWFEESA-N 3-chloro-2-methyl-n-[4-[2-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C([C@]1(OC[C@]2([H])C1)[H])N2C(=O)CC(N=1)=CSC=1NS(=O)(=O)C1=CC=CC(Cl)=C1C DWUNSAFRDBHZOU-STQMWFEESA-N 0.000 claims 1
- XRJYOOPROZMVTD-UHFFFAOYSA-N 3-chloro-2-methyl-n-[5-methyl-4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound N=1C(CC(=O)N2CCOCC2)=C(C)SC=1NS(=O)(=O)C1=CC=CC(Cl)=C1C XRJYOOPROZMVTD-UHFFFAOYSA-N 0.000 claims 1
- JOVCZOADHRKCLI-UHFFFAOYSA-N 3-chloro-n-[4-(2-methoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound COCCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 JOVCZOADHRKCLI-UHFFFAOYSA-N 0.000 claims 1
- IBCZFVVJSBMGBI-UHFFFAOYSA-N 3-chloro-n-[4-[2-(2-hydroxyethylamino)ethyl]-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCNCCO)=CS1 IBCZFVVJSBMGBI-UHFFFAOYSA-N 0.000 claims 1
- XXJRBYRRYDXBAK-UHFFFAOYSA-N 3-chloro-n-[4-[2-(3,4-dihydro-1h-isoquinolin-2-yl)-2-oxoethyl]-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CC(=O)N2CC3=CC=CC=C3CC2)=CS1 XXJRBYRRYDXBAK-UHFFFAOYSA-N 0.000 claims 1
- IKWXQEULPZNLEH-UHFFFAOYSA-N 3-chloro-n-[4-[2-(methanesulfonamido)ethyl]-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCNS(C)(=O)=O)=CS1 IKWXQEULPZNLEH-UHFFFAOYSA-N 0.000 claims 1
- CUVAORAJJTXNTP-GFCCVEGCSA-N 3-chloro-n-[4-[2-[(2r)-2,4-dimethylpiperazin-1-yl]-2-oxoethyl]-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound C[C@@H]1CN(C)CCN1C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 CUVAORAJJTXNTP-GFCCVEGCSA-N 0.000 claims 1
- KUXWEFJHUYNBNN-TXEJJXNPSA-N 3-chloro-n-[4-[2-[(2r,6s)-2,6-dimethylmorpholin-4-yl]-2-oxoethyl]-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 KUXWEFJHUYNBNN-TXEJJXNPSA-N 0.000 claims 1
- BZFCCDBKOGHSPH-UHFFFAOYSA-N 3-fluoro-n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound FC1=CC=CC(S(=O)(=O)NC=2SC=C(CCN3C(COCC3)=O)N=2)=C1 BZFCCDBKOGHSPH-UHFFFAOYSA-N 0.000 claims 1
- DZOVJGIRFXTALH-UHFFFAOYSA-N 4,5-dichloro-n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]thiophene-2-sulfonamide Chemical compound S1C(Cl)=C(Cl)C=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 DZOVJGIRFXTALH-UHFFFAOYSA-N 0.000 claims 1
- QKLDLIUPDVKUJI-UHFFFAOYSA-N 4-(1,3-benzodioxol-5-yl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C=1SC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=C3OCOC3=CC=2)=NC=1CC(=O)N1CCOCC1 QKLDLIUPDVKUJI-UHFFFAOYSA-N 0.000 claims 1
- RUTGRVOKCXTIRW-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=CC=C(S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)C=C1 RUTGRVOKCXTIRW-UHFFFAOYSA-N 0.000 claims 1
- PAAPGSDIHVKHJA-UHFFFAOYSA-N 4-(3-acetylphenyl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC(=O)C1=CC=CC(C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)=C1 PAAPGSDIHVKHJA-UHFFFAOYSA-N 0.000 claims 1
- VCPRDRUUVHTPGZ-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)C=C1 VCPRDRUUVHTPGZ-UHFFFAOYSA-N 0.000 claims 1
- QJQRNQNWXNMGTG-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C1CN(C)CCN1C1=CC=C(S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)C=C1 QJQRNQNWXNMGTG-UHFFFAOYSA-N 0.000 claims 1
- TZNDCHUGTISBJP-UHFFFAOYSA-N 4-(5-chlorothiophen-2-yl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound S1C(Cl)=CC=C1C1=CC=C(S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)C=C1 TZNDCHUGTISBJP-UHFFFAOYSA-N 0.000 claims 1
- VMFMBWQDDIDDNU-UHFFFAOYSA-N 4-(5-fluoro-2-methoxyphenyl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound COC1=CC=C(F)C=C1C1=CC=C(S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)C=C1 VMFMBWQDDIDDNU-UHFFFAOYSA-N 0.000 claims 1
- SXFRVZFEFYQRTN-UHFFFAOYSA-N 4-(5-methylthiophen-2-yl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound S1C(C)=CC=C1C1=CC=C(S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)C=C1 SXFRVZFEFYQRTN-UHFFFAOYSA-N 0.000 claims 1
- NGHRCUNMYJHQKD-UHFFFAOYSA-N 4-(furan-2-yl)-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C1COCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1C1=CC=CO1 NGHRCUNMYJHQKD-UHFFFAOYSA-N 0.000 claims 1
- ZXBXNYWGPIFHCW-UHFFFAOYSA-N 4-chloro-n-[4-[2-(diethylamino)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.CCN(CC)CCC1=CSC(NS(=O)(=O)C=2C=CC(Cl)=CC=2)=N1 ZXBXNYWGPIFHCW-UHFFFAOYSA-N 0.000 claims 1
- NHXSTXWKZVAVOQ-UHFFFAOYSA-N Ethyl furoate Chemical compound CCOC(=O)C1=CC=CO1 NHXSTXWKZVAVOQ-UHFFFAOYSA-N 0.000 claims 1
- IJNMHHJKXLKFJT-UHFFFAOYSA-N ethyl 2-[2-(benzenesulfonamido)-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC=CC=2)=N1 IJNMHHJKXLKFJT-UHFFFAOYSA-N 0.000 claims 1
- JJWLUBGKRMKXNK-UHFFFAOYSA-N ethyl 2-[2-(naphthalen-2-ylsulfonylamino)-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)=N1 JJWLUBGKRMKXNK-UHFFFAOYSA-N 0.000 claims 1
- JVAFXOOYGZUHAM-UHFFFAOYSA-N ethyl 2-[2-(quinolin-8-ylsulfonylamino)-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)=N1 JVAFXOOYGZUHAM-UHFFFAOYSA-N 0.000 claims 1
- CAAGINURIJZJFA-UHFFFAOYSA-N ethyl 2-[2-[(1-methylimidazol-4-yl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2N=CN(C)C=2)=N1 CAAGINURIJZJFA-UHFFFAOYSA-N 0.000 claims 1
- YVDPHJVUTMGFBK-UHFFFAOYSA-N ethyl 2-[2-[(2,4,6-trichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2Cl)Cl)=N1 YVDPHJVUTMGFBK-UHFFFAOYSA-N 0.000 claims 1
- XTSPBSIOOVDLFL-UHFFFAOYSA-N ethyl 2-[2-[(2,4,6-trifluorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(F)=CC=2F)F)=N1 XTSPBSIOOVDLFL-UHFFFAOYSA-N 0.000 claims 1
- PWVFWMRVAJPZQZ-UHFFFAOYSA-N ethyl 2-[2-[(2,4,6-trimethylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(C)=CC=2C)C)=N1 PWVFWMRVAJPZQZ-UHFFFAOYSA-N 0.000 claims 1
- RXLDVKZBTUCMEB-UHFFFAOYSA-N ethyl 2-[2-[(2,4-dichloro-6-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2C)Cl)=N1 RXLDVKZBTUCMEB-UHFFFAOYSA-N 0.000 claims 1
- AZFIPTGNCDPGCH-UHFFFAOYSA-N ethyl 2-[2-[(2,4-dichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2)Cl)=N1 AZFIPTGNCDPGCH-UHFFFAOYSA-N 0.000 claims 1
- OEECZQVLXUNUQW-UHFFFAOYSA-N ethyl 2-[2-[(2,5-dichlorothiophen-3-yl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C2=C(SC(Cl)=C2)Cl)=N1 OEECZQVLXUNUQW-UHFFFAOYSA-N 0.000 claims 1
- FCKASCFOIWCCQJ-UHFFFAOYSA-N ethyl 2-[2-[(2,5-dimethoxyphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=C(OC)C=2)OC)=N1 FCKASCFOIWCCQJ-UHFFFAOYSA-N 0.000 claims 1
- FIUOJUMQXLUVOT-UHFFFAOYSA-N ethyl 2-[2-[(2-chloro-4-fluorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(F)=CC=2)Cl)=N1 FIUOJUMQXLUVOT-UHFFFAOYSA-N 0.000 claims 1
- IWJABBCLSCEYRG-UHFFFAOYSA-N ethyl 2-[2-[(2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=CC=2)C)=N1 IWJABBCLSCEYRG-UHFFFAOYSA-N 0.000 claims 1
- ZCNWUMGMIAXUQD-UHFFFAOYSA-N ethyl 2-[2-[(2-nitrophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=CC=2)[N+]([O-])=O)=N1 ZCNWUMGMIAXUQD-UHFFFAOYSA-N 0.000 claims 1
- HLIXWSCWOHFWJI-UHFFFAOYSA-N ethyl 2-[2-[(3,4-dichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(Cl)C(Cl)=CC=2)=N1 HLIXWSCWOHFWJI-UHFFFAOYSA-N 0.000 claims 1
- PFPFBIQZBIPXNF-UHFFFAOYSA-N ethyl 2-[2-[(3,4-dimethoxyphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(OC)C(OC)=CC=2)=N1 PFPFBIQZBIPXNF-UHFFFAOYSA-N 0.000 claims 1
- XJVXNSMNVRSDPC-UHFFFAOYSA-N ethyl 2-[2-[(3,5-dichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(Cl)C=C(Cl)C=2)=N1 XJVXNSMNVRSDPC-UHFFFAOYSA-N 0.000 claims 1
- PDEKOPUOMNHLQP-UHFFFAOYSA-N ethyl 2-[2-[(3-bromo-5-chlorothiophen-2-yl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C2=C(C=C(Cl)S2)Br)=N1 PDEKOPUOMNHLQP-UHFFFAOYSA-N 0.000 claims 1
- ZTCSTONMUHDFKJ-UHFFFAOYSA-N ethyl 2-[2-[(3-bromophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(Br)C=CC=2)=N1 ZTCSTONMUHDFKJ-UHFFFAOYSA-N 0.000 claims 1
- GIDZENNFVLMYKK-UHFFFAOYSA-N ethyl 2-[2-[(3-nitrophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=N1 GIDZENNFVLMYKK-UHFFFAOYSA-N 0.000 claims 1
- UHAQMGZZUVKJHH-UHFFFAOYSA-N ethyl 2-[2-[(4-acetamido-3-chlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(Cl)C(NC(C)=O)=CC=2)=N1 UHAQMGZZUVKJHH-UHFFFAOYSA-N 0.000 claims 1
- CWRLDLCBUSKDDE-UHFFFAOYSA-N ethyl 2-[2-[(4-bromo-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Br)=CC=2)C)=N1 CWRLDLCBUSKDDE-UHFFFAOYSA-N 0.000 claims 1
- PGUXTMPTPRTMHK-UHFFFAOYSA-N ethyl 2-[2-[(4-bromophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(Br)=CC=2)=N1 PGUXTMPTPRTMHK-UHFFFAOYSA-N 0.000 claims 1
- KKXBMETYIBLJLL-UHFFFAOYSA-N ethyl 2-[2-[(4-butoxyphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound C1=CC(OCCCC)=CC=C1S(=O)(=O)NC1=NC(CC(=O)OCC)=CS1 KKXBMETYIBLJLL-UHFFFAOYSA-N 0.000 claims 1
- AAWVIKWDCOANTH-UHFFFAOYSA-N ethyl 2-[2-[(4-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2)C)=N1 AAWVIKWDCOANTH-UHFFFAOYSA-N 0.000 claims 1
- MSBRGTIONVCFPM-UHFFFAOYSA-N ethyl 2-[2-[(4-cyanophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)C#N)=N1 MSBRGTIONVCFPM-UHFFFAOYSA-N 0.000 claims 1
- MHIBAPFQSMMVMN-UHFFFAOYSA-N ethyl 2-[2-[(4-fluorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(F)=CC=2)=N1 MHIBAPFQSMMVMN-UHFFFAOYSA-N 0.000 claims 1
- JIHXZUUTKHVLNU-UHFFFAOYSA-N ethyl 2-[2-[(4-phenoxyphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 JIHXZUUTKHVLNU-UHFFFAOYSA-N 0.000 claims 1
- YRRUWWOAPIHJJB-UHFFFAOYSA-N ethyl 2-[2-[(4-phenylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 YRRUWWOAPIHJJB-UHFFFAOYSA-N 0.000 claims 1
- VJZNBJUIDMRTPW-UHFFFAOYSA-N ethyl 2-[2-[(4-propylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NC(CC(=O)OCC)=CS1 VJZNBJUIDMRTPW-UHFFFAOYSA-N 0.000 claims 1
- BAWTURGOYHDKPA-UHFFFAOYSA-N ethyl 2-[2-[(5-bromo-2-methoxyphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=C(Br)C=2)OC)=N1 BAWTURGOYHDKPA-UHFFFAOYSA-N 0.000 claims 1
- GJLFAKWHOGZISU-UHFFFAOYSA-N ethyl 2-[2-[[2-(trifluoromethyl)phenyl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC=CC=2)C(F)(F)F)=N1 GJLFAKWHOGZISU-UHFFFAOYSA-N 0.000 claims 1
- FLDPZLUGDUXEOR-UHFFFAOYSA-N ethyl 2-[2-[[3-(trifluoromethyl)phenyl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=C(C=CC=2)C(F)(F)F)=N1 FLDPZLUGDUXEOR-UHFFFAOYSA-N 0.000 claims 1
- JJHPJQFQWBOQJM-UHFFFAOYSA-N ethyl 2-[2-[[3-[[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl]sulfamoyl]benzoyl]amino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NC(=O)C=2C=C(C=CC=2)S(=O)(=O)NC=2SC=C(CC(=O)OCC)N=2)=N1 JJHPJQFQWBOQJM-UHFFFAOYSA-N 0.000 claims 1
- DAFDNRSHQQFNSQ-UHFFFAOYSA-N ethyl 2-[2-[[4-(3-chloro-2-cyanophenoxy)phenyl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(OC=3C(=C(Cl)C=CC=3)C#N)=CC=2)=N1 DAFDNRSHQQFNSQ-UHFFFAOYSA-N 0.000 claims 1
- ZODUISOKTTXHTP-UHFFFAOYSA-N ethyl 2-[2-[[4-(trifluoromethyl)phenyl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)C(F)(F)F)=N1 ZODUISOKTTXHTP-UHFFFAOYSA-N 0.000 claims 1
- LQNOTNMKIUTWJD-UHFFFAOYSA-N ethyl 2-[2-[[4-[[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl]sulfamoyl]benzoyl]amino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NC(=O)C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=C(CC(=O)OCC)N=2)=N1 LQNOTNMKIUTWJD-UHFFFAOYSA-N 0.000 claims 1
- REWJMTLJYJXMPA-UHFFFAOYSA-N ethyl 2-[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NS(=O)(=O)C=2C3=CC=CC(=C3C=CC=2)N(C)C)=N1 REWJMTLJYJXMPA-UHFFFAOYSA-N 0.000 claims 1
- SRRCAMPLVRPDHC-UHFFFAOYSA-N ethyl 2-oxo-2-[2-[(4-propylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NC(C(=O)C(=O)OCC)=CS1 SRRCAMPLVRPDHC-UHFFFAOYSA-N 0.000 claims 1
- PDEPXTWYXQSUAK-UHFFFAOYSA-N methyl 2-[2-[(2,4-dichloro-6-methylphenyl)sulfonylamino]-5-methyl-1,3-thiazol-4-yl]acetate Chemical compound S1C(C)=C(CC(=O)OC)N=C1NS(=O)(=O)C1=C(C)C=C(Cl)C=C1Cl PDEPXTWYXQSUAK-UHFFFAOYSA-N 0.000 claims 1
- BTWRJCDJRYLOCZ-UHFFFAOYSA-N methyl 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-5-methyl-1,3-thiazol-4-yl]acetate Chemical compound S1C(C)=C(CC(=O)OC)N=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C BTWRJCDJRYLOCZ-UHFFFAOYSA-N 0.000 claims 1
- QAJVSRSYPVAURA-UHFFFAOYSA-N methyl 2-[2-[[4-(3-chloro-2-cyanophenoxy)phenyl]sulfonylamino]-5-methyl-1,3-thiazol-4-yl]acetate Chemical compound S1C(C)=C(CC(=O)OC)N=C1NS(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC(Cl)=C1C#N QAJVSRSYPVAURA-UHFFFAOYSA-N 0.000 claims 1
- ZYBLYLRTWNHTON-UHFFFAOYSA-N methyl 2-[5-methyl-2-[(2,4,6-trichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound S1C(C)=C(CC(=O)OC)N=C1NS(=O)(=O)C1=C(Cl)C=C(Cl)C=C1Cl ZYBLYLRTWNHTON-UHFFFAOYSA-N 0.000 claims 1
- KASYRVNOWHARGW-UHFFFAOYSA-N n,n-di(propan-2-yl)-2-[2-[(4-propylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NC(CC(=O)N(C(C)C)C(C)C)=CS1 KASYRVNOWHARGW-UHFFFAOYSA-N 0.000 claims 1
- FDKSCNNPNTWASM-UHFFFAOYSA-N n,n-diethyl-2-[2-[(2,4,6-trichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetamide Chemical compound CCN(CC)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2Cl)Cl)=N1 FDKSCNNPNTWASM-UHFFFAOYSA-N 0.000 claims 1
- MSZAVOUFPRGJAK-UHFFFAOYSA-N n,n-diethyl-2-[2-[(4-phenylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetamide Chemical compound CCN(CC)C(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 MSZAVOUFPRGJAK-UHFFFAOYSA-N 0.000 claims 1
- AWAACVVVLZSRMV-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-2-[2-(naphthalen-1-ylsulfonylamino)-1,3-thiazol-4-yl]acetamide Chemical compound C1=C2OCOC2=CC(CNC(CC=2N=C(NS(=O)(=O)C=3C4=CC=CC=C4C=CC=3)SC=2)=O)=C1 AWAACVVVLZSRMV-UHFFFAOYSA-N 0.000 claims 1
- OABDREFMJCKLIU-UHFFFAOYSA-N n-(2-methoxyethyl)-2-[2-[(4-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetamide Chemical compound COCCNC(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(C)=CC=2)=N1 OABDREFMJCKLIU-UHFFFAOYSA-N 0.000 claims 1
- PFWDLCWNUMFJJK-UHFFFAOYSA-N n-(furan-2-ylmethyl)-2-[2-(naphthalen-1-ylsulfonylamino)-1,3-thiazol-4-yl]acetamide Chemical compound C=1SC(NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=NC=1CC(=O)NCC1=CC=CO1 PFWDLCWNUMFJJK-UHFFFAOYSA-N 0.000 claims 1
- HEOXDBQVGHVNLH-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-2-[2-(naphthalen-1-ylsulfonylamino)-1,3-thiazol-4-yl]acetamide Chemical compound C1=CC=C2C(CCNC(CC=3N=C(NS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)SC=3)=O)=CNC2=C1 HEOXDBQVGHVNLH-UHFFFAOYSA-N 0.000 claims 1
- NHJOUIXWKCQUBU-UHFFFAOYSA-N n-[2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl]-n-ethylacetamide Chemical compound CCN(C(C)=O)CCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 NHJOUIXWKCQUBU-UHFFFAOYSA-N 0.000 claims 1
- LWXASGPYUQKPDV-UHFFFAOYSA-N n-[2-chloro-4-[[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]sulfamoyl]phenyl]acetamide Chemical compound C1=C(Cl)C(NC(=O)C)=CC=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 LWXASGPYUQKPDV-UHFFFAOYSA-N 0.000 claims 1
- LSPRNCRLZWVZMS-UHFFFAOYSA-N n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]-4-[4-(trifluoromethoxy)phenyl]benzenesulfonamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=C(S(=O)(=O)NC=2SC=C(CC(=O)N3CCOCC3)N=2)C=C1 LSPRNCRLZWVZMS-UHFFFAOYSA-N 0.000 claims 1
- YYRBCTCJEIQSTN-UHFFFAOYSA-N n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]-4-pyridin-4-ylbenzenesulfonamide Chemical compound C1COCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1C1=CC=NC=C1 YYRBCTCJEIQSTN-UHFFFAOYSA-N 0.000 claims 1
- MRMBTSXGNCSWEL-UHFFFAOYSA-N n-[4-(2-morpholin-4-ylethyl)-1,3-thiazol-2-yl]-4-propylbenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NC(CCN2CCOCC2)=CS1 MRMBTSXGNCSWEL-UHFFFAOYSA-N 0.000 claims 1
- IQYUHYFDRRCXDI-UHFFFAOYSA-N n-[4-(2-oxo-2-piperidin-1-ylethyl)-1,3-thiazol-2-yl]-4-phenylbenzenesulfonamide Chemical compound C1CCCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1C1=CC=CC=C1 IQYUHYFDRRCXDI-UHFFFAOYSA-N 0.000 claims 1
- PEXLPZAFFFVDLN-UHFFFAOYSA-N n-[4-(2-oxo-2-piperidin-1-ylethyl)-1,3-thiazol-2-yl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NC(CC(=O)N2CCCCC2)=CS1 PEXLPZAFFFVDLN-UHFFFAOYSA-N 0.000 claims 1
- DHGMBKNUQFOXNJ-UHFFFAOYSA-N n-[4-(2-oxo-2-thiomorpholin-4-ylethyl)-1,3-thiazol-2-yl]-4-phenylbenzenesulfonamide Chemical compound C1CSCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1C1=CC=CC=C1 DHGMBKNUQFOXNJ-UHFFFAOYSA-N 0.000 claims 1
- GHPAJYUHXJJXPB-UHFFFAOYSA-N n-[4-(2-oxo-2-thiomorpholin-4-ylethyl)-1,3-thiazol-2-yl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NC(CC(=O)N2CCSCC2)=CS1 GHPAJYUHXJJXPB-UHFFFAOYSA-N 0.000 claims 1
- YRZIFGRNSHSHKU-UHFFFAOYSA-N n-[4-[2-(1,1-dioxo-1,4-thiazinan-4-yl)-2-oxoethyl]-1,3-thiazol-2-yl]-4-propylbenzenesulfonamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NC(CC(=O)N2CCS(=O)(=O)CC2)=CS1 YRZIFGRNSHSHKU-UHFFFAOYSA-N 0.000 claims 1
- PKQBQRASDIOPOK-UHFFFAOYSA-N n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]-4-phenoxybenzenesulfonamide Chemical compound O=C1COCCN1CCC1=CSC(NS(=O)(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 PKQBQRASDIOPOK-UHFFFAOYSA-N 0.000 claims 1
- YDLJYKPHLDWGPU-UHFFFAOYSA-N n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]-5-pyridin-2-ylthiophene-2-sulfonamide Chemical compound O=C1COCCN1CCC1=CSC(NS(=O)(=O)C=2SC(=CC=2)C=2N=CC=CC=2)=N1 YDLJYKPHLDWGPU-UHFFFAOYSA-N 0.000 claims 1
- ZGFGGMMCEBVIEZ-UHFFFAOYSA-N n-[5-methyl-4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]-4-phenylbenzenesulfonamide Chemical compound N=1C(CC(=O)N2CCOCC2)=C(C)SC=1NS(=O)(=O)C(C=C1)=CC=C1C1=CC=CC=C1 ZGFGGMMCEBVIEZ-UHFFFAOYSA-N 0.000 claims 1
- ITSYGEVZNPQFOG-UHFFFAOYSA-N n-ethyl-n-methyl-2-[2-[(2,4,6-trichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetamide Chemical compound CCN(C)C(=O)CC1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2Cl)Cl)=N1 ITSYGEVZNPQFOG-UHFFFAOYSA-N 0.000 claims 1
- NSBJXAREJWGDLL-UHFFFAOYSA-N n-ethyl-n-methyl-2-[2-[(4-phenylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetamide Chemical compound CCN(C)C(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 NSBJXAREJWGDLL-UHFFFAOYSA-N 0.000 claims 1
- QRGPSAWENJEUME-UHFFFAOYSA-N n-ethyl-n-methyl-2-[2-[(4-propylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)NC1=NC(CC(=O)N(C)CC)=CS1 QRGPSAWENJEUME-UHFFFAOYSA-N 0.000 claims 1
- JLCVXVYTCBEECT-UHFFFAOYSA-N n-methyl-2-[2-[(4-phenylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-n-propan-2-ylacetamide Chemical compound CC(C)N(C)C(=O)CC1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 JLCVXVYTCBEECT-UHFFFAOYSA-N 0.000 claims 1
- KTNAKTBGOFTHKY-UHFFFAOYSA-N tert-butyl 4-[2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetyl]piperazine-1-carboxylate Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CC(=O)N2CCN(CC2)C(=O)OC(C)(C)C)=CS1 KTNAKTBGOFTHKY-UHFFFAOYSA-N 0.000 claims 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 abstract 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 abstract 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 8
- 150000002431 hydrogen Chemical group 0.000 description 8
- YDPRNGAPPNPYQQ-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound C1CN(C)CCN1C(=O)CC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 YDPRNGAPPNPYQQ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 229960000890 hydrocortisone Drugs 0.000 description 5
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- ZTVIKZXZYLEVOL-DGKWVBSXSA-N 2-hydroxy-2-phenylacetic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical group C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-DGKWVBSXSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- IEMGWBMVQLVHEY-UHFFFAOYSA-N ethyl 2-(3-amino-6,7-dihydro-5h-cyclopenta[b]pyridin-7-yl)acetate Chemical compound NC1=CN=C2C(CC(=O)OCC)CCC2=C1 IEMGWBMVQLVHEY-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- FUFLCEKSBBHCMO-KJQYFISQSA-N 11-dehydrocorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 FUFLCEKSBBHCMO-KJQYFISQSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AYTPIVIDHMVGSX-UHFFFAOYSA-N 2,1,3-benzoselenadiazole Chemical compound C1=CC=CC2=N[se]N=C21 AYTPIVIDHMVGSX-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- 125000006516 2-(benzyloxy)ethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- SQGWOBDUXQBFJO-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetic acid Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CC(O)=O)=CS1 SQGWOBDUXQBFJO-UHFFFAOYSA-N 0.000 description 1
- DHILZBKTQNBASR-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl furan-2-carboxylate Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCOC(=O)C=2OC=CC=2)=CS1 DHILZBKTQNBASR-UHFFFAOYSA-N 0.000 description 1
- MNYDWIWWEGDUMZ-UHFFFAOYSA-N 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]ethyl n,n-diethylcarbamate Chemical compound CCN(CC)C(=O)OCCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 MNYDWIWWEGDUMZ-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 description 1
- JQAGIZSPAQASSK-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CC(=O)N2CCOCC2)=CS1 JQAGIZSPAQASSK-UHFFFAOYSA-N 0.000 description 1
- BWXKSRWYBGUSHW-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(2-methyl-3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound O=C1C(C)OCCN1CCC1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 BWXKSRWYBGUSHW-UHFFFAOYSA-N 0.000 description 1
- UMJPVWFIBILILQ-UHFFFAOYSA-N 3-methyl-2-propan-2-ylbutanamide Chemical compound CC(C)C(C(C)C)C(N)=O UMJPVWFIBILILQ-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- JVFCCRJSBNUDDU-UHFFFAOYSA-N 4-phenylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=CC=CC=C1 JVFCCRJSBNUDDU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 0 Bc1c(***)nc(*S(*)(=O)=O)[s]1 Chemical compound Bc1c(***)nc(*S(*)(=O)=O)[s]1 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZYUZLEUJKZZXNN-UHFFFAOYSA-N C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 Chemical group C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 ZYUZLEUJKZZXNN-UHFFFAOYSA-N 0.000 description 1
- BRAIZMGEVOORLF-UHFFFAOYSA-N C1CSCC(N1O)O Chemical compound C1CSCC(N1O)O BRAIZMGEVOORLF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000003865 brosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)S(*)(=O)=O 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- GZLJHVLKSZQICO-UHFFFAOYSA-N ethyl 2-[2-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-thiazol-4-yl]-2-oxoacetate Chemical compound CCOC(=O)C(=O)C1=CSC(NS(=O)(=O)C=2C(=C(Cl)C=CC=2)C)=N1 GZLJHVLKSZQICO-UHFFFAOYSA-N 0.000 description 1
- SSTFTUKNWXIXKH-UHFFFAOYSA-N ethyl 2-oxo-2-[2-[(2,4,6-trichlorophenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)C(=O)C1=CSC(NS(=O)(=O)C=2C(=CC(Cl)=CC=2Cl)Cl)=N1 SSTFTUKNWXIXKH-UHFFFAOYSA-N 0.000 description 1
- PVWVVNUNHXAKGT-UHFFFAOYSA-N ethyl 2-oxo-2-[2-[(4-phenylphenyl)sulfonylamino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)C(=O)C1=CSC(NS(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 PVWVVNUNHXAKGT-UHFFFAOYSA-N 0.000 description 1
- WDAXFOBOLVPGLV-UHFFFAOYSA-N ethyl isobutyrate Chemical compound CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 description 1
- GZXSDYYWLZERLF-UHFFFAOYSA-N ethyl n-ethylcarbamate Chemical compound CCNC(=O)OCC GZXSDYYWLZERLF-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- KDBCMBSJLWWVBF-UHFFFAOYSA-N n-[4-(2-morpholin-4-yl-2-oxoethyl)-1,3-thiazol-2-yl]-4-phenoxybenzenesulfonamide Chemical compound C1COCCN1C(=O)CC(N=1)=CSC=1NS(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 KDBCMBSJLWWVBF-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 150000003145 progesterone derivatives Chemical class 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
The invention relates to a method for promoting wound healing, said method comprising administering to a mammal, including man, in need of such promotion an effective amount of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1, wherein the said 11b-HSD1 inhibitor has the formula (I) wherein T, B, X, Y, R1 and R2 are as defined in the specification. These compounds may also be used in the manufacture of a medicament for promoting wound healing.
Description
NEW USE I
RELATED APPLICATIONS
This application claims priority to Swedish application number 0301882-7, filed on June 25, 2003, the contents of which are incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to the use of chemical compounds for wound healing, said compounds acting on the human 11-(3-hydroxysteroid dehydrogenase type 1 enzyme (11 (3HSD1).
BACKGROUND ART
Cortisol performs a broad range of metabolic functions and other functions.
The multitude of glucocorticoid action is exemplified in patients with prolonged increase in plasma glucocorticoids, so called "Cushing's syndrome". Patients with Cushing's syndrome have prolonged increase in plasma glucocorticoids and exhibit impaired glucose tolerance, type 2 diabetes, central obesity, and osteoporosis. These patients also is have impaired wound healing and brittle skin (1).
Glucocorticoids have been shown to increase risk of infection and delay healing of open wounds (2). Patients treated with glucocorticoids have 2-5-fold increased risk of complications when undergoing surgery (3).
The European patent application No. EP 0902288 discloses a method for diagnosing the status of wound healing in a patient, comprising detecting cortisol levels in said wound.
The authors suggest that elevated levels of cortisol in wound fluid, relative to normal plasma levels in healthy individuals, correlates with large, non-healing wounds (4).
In humans, the 11 (3-HSD catalyzes the conversion of cortisol to cortisone, and vice versa. The parallel function of 11(3-HSD in rodents is the interconversion of _2_ corticosterone and 11-dehydrocorticosterone (5). Two isoenzymes of 11 (3-HSD, 11 [3-HSD 1 and 11 (3-HSD2, have been characterized, and differ from each other in function and tissue distribution (6). Like GR, 11 [3-HSD 1 is expressed in numerous tissues like liver, adipose tissue, adrenal cortex, gonads, lung, pituitary, brain, eye etc (7-9). The function of 11 (3-HSD 1 is to fine-tune local glucocorticoid action. 11 [3-HSD
activity has been shown in the skin of humans and rodents, in human fibroblasts and in rat skin pouch tissue (10-13).
Wound healing consists of serial events including inflammation, fibroblast proliferation, secretion of ground substances, collagen production, angiogenesis, wound contraction and epithelialization. It can be divided in three phases; inflammatory, proliferative and remodeling phase (reviewed in (2)).
In surgical patients, treatment with glucocorticoids increases risk of wound infection is and delay healing of open wounds. It has been shown in animal models that restraint stress slows down cutaneous wound healing and increases susceptibility to bacterial infection during wound healing. These effects were reversed by treatment with the glucocorticoid receptor antagonist RU486 (14, 15). Glucocorticoids produce these effects by suppressing inflammation, decrease wound strength, inlubit wound 2o contracture and delay epithelialization (2). Glucocorticoids influence wound healing by interfering with production or action of cytokines and growth factors like IGF, TGF-(3, EGF, KGF and PDGF (16-19). It has also been shown that glucocorticoids decrease collagen synthesis in rat and mouse skin in vivo and in rat and human fibroblasts (20).
2s WO 01/90090 discloses compounds of the formula (I) as defined hereinafter, which compounds inhibit the human 11(3-HSD1, and may be useful for treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders and immune disorders.
Other 11(3-HSD1 inhibitors axe disclosed in e.g. WO 01/90091; WO 01/90092; WO
01/90093; WO 01/90094; WO 03/044000; WO 03/044009; WO 03/043999; and 3o Swedish patent application No. SE 0301504-7, filed on May 21, 2003. WO
relates to glycyrrhetinic acid derivatives, progesterone and progesterone derivatives as 11 [3-HSD 1 inhibitors for wound healing. However, the use of the 11 [3-HSD 1 inhibitors according to the present invention for wound healing has not previously been disclosed.
DISCLOSURE OF THE INVENTION
It has surprisingly been found that the present inhibitors of 11 (3-HSD 1 are useful for the promotion of wound healing. Consequently, in a first aspect this invention provides a method for promoting wound healing, said method comprising administering to a mammal, including man, in need of wound healing an effective amount of an inhibitor of 11 (3-hydroxysteroid dehydrogenase type l, wherein the inhibitor of 11 (3-hydroxysteroid dehydrogenase type 1 is a compound of the formula (I):
to R~
T~S/N /N X~Y/R2 O \O
S
(I) wherein is T is an aryl ring or heteroaryl ring or aryl-C2-alkenyl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1_6-alkyl, optionally halogenated Cl_6-alkoxy, C1_6-alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono- or di-substituted, amide which is optionally mono- or di-substituted, aryloxy, arylsulfonyl, 2o arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings can further be optionally substituted in one or more positions independently of each other by C1_6-acyl, Cl_6-alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C1_6-alkyl, optionally halogenated C1_6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2-thienylmethylamino or ({[4-(2-ethoxy-2-2s oxoethyl)-1,3-thiazol-2-yl]amino]carbonyl);
Rl is hydrogen or C1_6-alkyl;
X is CHZ or CO;
Y is CH2, CO or a single bond;
B is hydrogen or C1_6-alkyl;
Rz is selected from C1_6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaxninomethyl, methylsulfonyloxymethyl, 3-oxo-4-morpholinolinylmethylene, C1_6-alkoxycarbonyl, and 5-methyl-1,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1_6-alkyl, optionally halogenated C1_6-alkylsulfonyl, C1_6-alkoxy, 2-methoxyethyl, 2-hydroxyethyl, l0 1-methylimidazolylsulfonyl, C1_6-acyl, cyclohexyhnethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl and C1_6-alkyl substituted with one or more aryl or heteroaryl, or NR3R4 represent together heterocyclic systems which can be imidazole, piperidine, pyrrolidine, piperazine, morpholine, oxazepine, oxazole, thiomorpholine, 1,1-Is dioxidothiomorpholine, 2-(3,4-dihydro-2(1H)isoquinolinyl), (1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems can be optionally substituted by CI_6-alkyl, Cl_6-acyl, hydroxy, oxo, t-butoxycarbonyl;
OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1_s-alkyl or form together morpholinyl;
2o R50, wherein RS is hydrogen, optionally halogenated C1_6-alkyl, aryl, heteroaryl, C1_6-aryl, C1_6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof.
2s It is preferred that:
T is selected from 5-chloro-1,3-dimethyl-1H-pyrazol-4-yl; 4-chloro-2,3,1-benzoxadiazolyl; 5-(dimethylamino)-1-naphthyl; 1-methylimidazol-4-yl; 1-naphthyl; 2-naphthyl; (E)-2-phenylethenyl; 8-quinolinyl;
3o thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3-isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1-methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl;
phenyl substituted with one or more of acetylamino, 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, 1,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5-bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro-2-cyanophenoxy, 4-chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ( f [4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2-furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl-1-piperazinyl, 4-methyl-1-piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4-morpholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3-pyridylmethylamino, 1-pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, io trifluoromethoxy, 4-trifluoromethoxyphenyl, and trifluoromethyl;
Rl is hydrogen or methyl;
X is CHZ or CO;
Y is CHZ, CO or a single bond;
B is hydrogen or methyl;
2o RZ is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-morpholinolinyhnethylene, ethoxycarbonyl, 5-methyl-1,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, 1,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexylmethyl, 2s ethyl, 2-furylcarbonyl, 2-furylmethyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl)ethyl, isopropyl, methoxy, 2-methoxyethyl, methyl, 4-(1-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, propyl, trifluoromethylsulfonyl; or NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2-(3,4-dihydro-2(1H)isoquinolinyl), (2R,6S)-2,6-dimethylmorpholinyl, (2R)-2,4-dimethyl-1-so piperazinyl, 2-hydroxy-3-oxomorpholinyl, imidazolyl, 2-methyl-3-oxomorpholinyl, 4-methyl-2-oxopiperazinyl, 4-methylpiperazinyl, morpholinyl, (1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomorpholinyl, 3-oxo-1,4-oxazepinyl, 2-oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomorpholinyl;
1,1-dioxido-thiomorpholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together morpholinyl;
R50, wherein RS is selected from acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, propionyl, 3-pyridinyl, and 2,2,2-trifluoroethyl.
The following compounds are especially preferred:
io ethyl (2-{[(2,4-dichloro-5-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-(2-[[(4-chlorophenyl)sulfonyl]amino]-1,3-thiazole-4-yl)acetate, ethyl 2-(2- { [ (4-chloro-2, 5-dimethylphenyl) sulfonyl] amino ~ -1,3-thiazol-yl)acetate, ~s ethyl2-(2-{[(2,4-difluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-(2-(((4-methylphenyl)sulfonyl)amino)-1,3-thiazol-4-yl)acetate, ethyl 2-(2-{[(2,5-dichloro-3-thienyl)sulfonyl]amino-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-(2- { [(3-chloro-2-methylphenyl)sulfonyl] amino }-1,3-thiazol-4-yl)acetate, 2o ethyl 2-{2-[([ l,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl) acetate, ethyl 2-(2- { [ (3 -bromophenyl) sulfonyl] amino ) -1, 3-thiazol-4-yl) acetate, ethyl (2-{[(4-nitrophenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-nitrophenyl)sulfonyl]amino-1,3-thiazol-4-yl)acetate, 2s ethyl (2-{[(3-methylphenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-chlorophenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-fluorophenyl)sulfonyl]amino)-1,3-thia,zol-4-yl)acetate, ethyl (2-{[(3-fluorophenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetate, ethyl {2-[(phenylsulfonyl)amino]-1,3-thiazol-4-yl~ acetate, 3o ethyl (2-{[(4-isopropylphenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetate, ethyl [2-({[3-({,[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl] amino} carbonyl)phenyl] sulfonyl~ amino)-1,3-thiazol-4-yl] acetate, ethyl [2-( f [4-( { [4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl] amino} carbonyl)phenyl]sulfonyl} amino)-1,3-thiazol-4-yl] acetate, ethyl (2- f [(2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-( f [2-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, s ethyl [2-(~[3-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-( f [4-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl 2-(2- f [(4-bromophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(2-nitrophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, to ethyl (2- f [(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(2,4-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(5-fluoro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-methoxy-4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, is ethyl (2- f [(3,5-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-( f [4-(3-chloro-2-cyanophenoxy)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, , ethyl (2-~[(3,4-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(4-butoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, 2o ethyl (2- f [(4-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[4-(acetylamino)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl ~2-[(8-quinolinylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2- f [(3,4-dirnethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-iodophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, 2s ethyl (2-{[(3-chloro-4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-( f [5-(dimethylamino)-1-naphthyl]sulfonyl}amino)-1,3-thiazol-4-yl] acetate, ethyl (2- f [(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(5-bromo-2-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(2,5-dimethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl ~2-[(2-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl f 2-[(mesitylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-~[(3-bromo-5-chloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, _g_ ethyl {2-[({5-[(benzoylamino)methyl]-2-thienyl}sulfonyl)amino]-1,3-thiazol-4-yl } acetate, ethyl {2-[({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl} sulfonyl)amino]-1,3-thiazol-4-yl} acetate, s ethyl (2-{[(4-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl {2-[({5-[2-(methylsulfanyl)-4-pyrimidinyl]-2-thienyl}sulfonyl)amino]-1,3-thiazol-4-yl} acetate, ethyl (2-{[(3-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,4,5-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, to ethyl [2-({[(E)-2-phenylethenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,3,4-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-2,5-difluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl]acetate, ethyl [2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,3-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, is ethyl (2-{[(2-bromophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4,5-dichloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[4-(phenylsulfonyl)-2-thienyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-({[5-(phenylsulfonyl)-2-thienyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,6-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, 2o ethyl (2-{[(2-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-({[4-(acetylamino)-3-chlorophenyl]sulfonyl}amino)-1,3-thiazol-4-y1] acetate, ethyl (2-{[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino}-1,3-thiazol-yl)acetate, 2s ethyl (2-{[(3-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-5-chloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl} acetate, ethyl (2-{[(2,5-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-methanesulfonylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, so ethyl (2-{[(2-methanesulfonylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-2-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-methyl-4-trifluoromethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4 yl)acetate, ethyl (2-{[(2,3,4-trifluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(4-chloro-2,3,1-benzoxadiazolyl)sulfonyl]amino}-1,3-thiazol-4 yl)acetate, ethyl (2- f [(2,4,6-trifluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, s ethyl (2-~[(S-carboxy-4-chloro-2-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(2-(5-chlorothienyl))sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(2-chloro-4-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-(5-(3-isoxazolo)thienyl))sulfonyl]amino}-1,3-thiazol-4-yl)acetate, to ethyl (2-~[(4-bromo-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(4-phenoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(4-chloro-2,6-dimethylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(2-methyl-4-trifluoromethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, is ethyl (2-~[(2,4-bis(trifluoromethyl)phenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ~ . .
ethyl 2-{2-[[(3-chloro-2-methylphenyl)sulfonyl](methyl)amino]-1,3-thiazol-4-yl} acetate, ethyl oxo(2- f [(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, 2o ethyl (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)(oxo)acetate, ethyl oxo(2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl {2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}(oxo)acetate, ethyl (2- f [(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-2s yl)(oxo)acetate, 2-(2- f [(4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, 2-(2- f [(2,5-dichloro-3-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, (2-{[(2-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, so isopropyl 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, phenyl 2-(2- { [(3-chloro-2-methylphenyl)sulfonyl] amino } -1, 3-thiazol-4-yl) acetate, methyl (2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl f 2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-5-methyl-1,3-thiazol-4-yl ] acetate, methyl (2-~[(4-chlorophenyl)sulfonyl]amino}-5-methyl-1,3-thiazol-4-yl)acetate, methyl (2- f [(3-chloro-2-methylphenyl)sulfonyl]amino]-5-methyl-1,3-thiazol-4 s yl)acetate, methyl [2-( f [4-(3-chloro-2-cyanophenoxy)phenyl]sulfonyl~amino)-5-methyl-1,3-thiazol-4-yl]acetate, methyl (5-methyl-2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl (5-methyl-2- f [(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-1 o yl)acetate, methyl (2- f [(2,4-dichloro-6-methylphenyl)sulfonyl]amino]-5-methyl-1,3-thiazo1-4-yl)acetate, N-(2-methoxyethyl)-2-(2- f [(4-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)acetamide, Is 2-(2-~[(2,S-dichloro-3-thienyl)sulfonyl]amino)-1,3-thia,zol-4-yl)-N-methylacetamide, N-(1,3-benzodioxol-5-ylmethyl)-2-~2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl] acetamide, N-(2-furylmethyl)-2- f2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, 20 2-(2- f [(2,4-difluorophenyl)sulfonyl]amino-1,3-thiazol-4-yl)-N-ethylacetamide, N-isopropyl-2- f 2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl} acetamide, N-[2-( 1 H-indo l-3-yl) ethyl]-2- ~2-[( 1-naphthylsulfonyl) amino]-1, 3-thi azol-4-yl] acetamide, N-(cyclohexylmethyl)-2- f 2-[(phenylsulfonyl)amino]-1,3-thiazol-4-yl}
acetamide, 2s 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)-N-methylacetamide, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)-N-ethylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)-N-3o phenylacetamide, 2-(2-~[(4-chlorophenyl)sulfonyl]amino]-1,3-thiazol-4-yl)-N-(2-furylmethyl)acetamide, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)acetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-diethylacetamide, 2- f 2-[([ l,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N,N-diethylacetamide, s N,N-diethyl-2-(2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2- ~ [(2,4-dichloro-6-methylphenyl)sulfonyl] amino } -1, 3-thiazol-4-yl)-N,N-diethylacetamide, N,N-diethyl-2-(2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, l0 2-f2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N,N-diisopropylacetamide, N,N-diisopropyl-2-(2- f [(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2- ~ [(2,4-dichloro-6-methylphenyl) sulfonyl] amino } -1,3-thiazol-4-yl)-N,N-1 s diisopropylacetamide, N,N-diisopropyl-2-(2- { [(2,4,6-trichlorophenyl)sulfonyl] amino}-1,3-thiazol-4-yl)acetamide, 2-(2- ~ [(3-chloro-2-methylphenyl) sulfonyl] amino } -1, 3-thiazol-4-yl)-N,N-diisopropylacetamide, 20 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-dipropylacetamide, N-benzyl-2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethylacetamide, 2-(2-~[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-2s dimethylacetamide, 3-chloro-N- f 4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-methyl-N-phenylacetamide, so 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-isopropyl-N-methylacetamide, 2- f 2-[([l,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N-isopropyl-N-methylacetamide, N-ethyl-N-methyl-2-(2- f [(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2- f [(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethyl-N-methylacetamide, s N-ethyl-N-methyl-2-(2-~[(4-propylphenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetamide, 2- f 2-[([ 1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl)-N-ethyl-N-methylacetamide, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethyl-N-t o methylacetamide, 3-chloro-2-methyl-N- f 4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,3-thiazol-2-yl)benzenesulfonamide, 3-chloro-2-methyl-N- {4-[2-oxo-2-( 1-piperidinyl)ethyl]-1,3-thiazol-2-yl)benzenesulfonamide, is N-~4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl)[l,l'-biphenyl]-4-sulfonamide, N-~4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide, 2,4-dichloro-6-methyl-N- f 4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-2o yl}benzenesulfonamide, 2,4,6-trichloro-N- f 4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl)benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl)benzenesulfonamide, 2s 2,4,6-trichloro-N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl)benzenesulfonamide, 2,4-dichloro-6-methyl-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl} [ 1,1'-biphenyl]-4-3o sulfonamide, N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl)-4-propylbenzenesulfonamide, 2,4-dichloro-N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-chloro-2,6-dimethyl-N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl } b enzenesulfonamide, s N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-phenoxybenzenesulfonamide, 2-methyl-N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-(trifluoromethoxy)benzenesulfonamide, N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-2,4-bis(trifluoromethyl)benzenesulfonamide, 4-bromo-2-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(2-furyl)-N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl} benzenesulfonamide, is 4-(5-fluoro-2-methoxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl} benzenesulfonamide, 4-(5-methyl-2-thienyl)-N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-acetylphenyl)-N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-2o yl}benzenesulfonamide, 4-(4-trifluoromethoxyphenyl)-N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3,4-dichlorophenyl)-N- ~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl} benzenesulfonamide, 2s 4-(3,4-methylenedioxyphenyl)-N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(5-chloro-2-thienyl)-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl } benzenesulfonamide, 4-(4-pyridyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-y1 } b enzenesulfonamide, 4-(3-acetylaminophenyl)-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-thienyl)-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(2-thienyl)-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, s 4-(4-carboxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methylsulfanylphenyl)-N- {4-[2-(4-morpholinyl)-2-oxo ethyl]-1,3-thi azol-yl}benzenesulfonamide, 4-(3,5-bis(trifluoromethyl)phenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-chlorophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazo1-2-y1 } b enzenesulfonamide, 4-(3-nitrophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, is 4-(2-benzofuryl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(1-pyrrolidino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methyl-1-piperidino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-2o y1 } benzenesulfonasnide, 4-(benzeneamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(benzylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2s 4-(2-thienylmethylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-morpholinyl)-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methyl-1-piperazinyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-3o yl}benzenesulfonamide, 4-(3-pyridylmethylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4-dichloro-6-methyl-N- ~5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N- ~5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl] [ 1,1'-biphenyl]-4-sulfonamide, s 2,4,6-trichloro-N- f 5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-~5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-(4- f 2-[(2R,6S)-2,6-dimethylmorpholinyl]-2-oxoethyl]-1,3-thiazol-2-1 o yl)-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-(4- f2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]kept-5-yl]-2-oxoethyl}-1,3-thiazol-2-yl)benzenesulfonamide, 3-chloro-2-methyl-N- f 4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, is N-f4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}[1,1'-biphenyl]-4-sulfonamide, N-~4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl]-4-propylbenzenesulfonamide, 2,4-dichloro-6-methyl-N- f 4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-2o yl]benzenesulfonamide, 2,4,6-trichloro-N-~4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N- ~4-[2-( 1,1-dioxido-4-thiomorpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl} -4-propylbenzenesulfonamide, 2s tert-butyl 4-[(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)acetyl]-1-piperazinecarboxylate, 4-acetyl-(4-[(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetyl])-1-piperazine, 4-[(2-~[(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)acetyl]-1-3o piperazine trifluoroacetate, 3-chloro-2-methyl-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide hydrochloride, 2-methyl-N- f 4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-(trifluoromethoxy)benzenesulfonamide, 2,4-dichloro-6-methyl-N- {4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, s 2,4-dichloro-N-~4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-(4- f 2-[(2R)-2,4-dimethylpiperazinyl]-2-oxoethyl}-1,3-thiazol-2-yl)-2-methylbenzenesulfonamide, 2-(2- ~ [(3-chloro-2-methylphenyl)sulfonyl] amino}-1,3-thiazol-4-yl)-N-methoxy-lo N-methylacetamide, 3-chloro-2-methyl-N-[4-(2-oxopentyl)-1,3-thiazol-2-yl]benzenesulfonamide, 4-chloro-N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]benzenesulfonamide, 3-chloro-N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-ethoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, Is 3-chloro-N-[4-(2-isopropoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, N- ~4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-yl } -3-chloro-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-methoxyethyl)-1,3-thiazol-2-yl]-2-riiethylbenzenesulfonamide, ao 3-chloro-N-{4-[2-(2-fluoroethoxy)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N- f 4-[2-(2,2,2-trifluoroethoxy)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N- f 4-[2-(2-pyridinylsulfanyl)ethyl]-1,3-thiazol-2-2s yl}benzenesulfonamide, 3-chloro-2-methyl-N- f 4-[2-(3-pyridinyloxy)ethyl]-1,3-thiazol-2-yl } benzenesulfonamide, 3-chloro-2-methyl-N- f 4-[2-methylsalicylethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2-(2- ~ [(3-chloro-2-methylphenyl)sulfonyl] amino } -1,3-thiazol-4-yl)ethyl methanesulfonate, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl acetate, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl propionate, 2-(2-~[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl 2-methylpropanoate, s 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl2-furoate, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl benzoate, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl 4-1 o morpholinecarboxylate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl diethylcarbamate, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl ethylcarbamate, is N-[4-(2-azidoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide, N-[4-(2-aminoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide hydrochloride, 4-chloro-N-~4-[2-(diethylamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 20 3-chloro-N-{4-[2-(diethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide hydrochloride, 3-chloro-N-{4-[2-(1-imidazolyl)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide hydrochloride, 3-chloro-2-methyl-N-~4-[2-(4-methyl-1-piperazinyl)ethyl]-1,3-thiazol-2-2s yl}benzenesulfonamide dihydrochloride, 3-chloro-2-methyl-N-~4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 3-chloro-2-methyl-N-{4-[(4-morpholinyl)methyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 30 2,4,6-trichloro-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2,4-dichloro-N-~4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2,4-dichloro-6-methyl-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2 yl}benzenesulfonamide hydrochloride, N- {4-[2-(4- morpholinyl)ethyl]-1,3-thiazol-2-yl~ -4-propylbenzenesulfonamide hydrochloride, s 3-chloro-N-{4-[2-(ethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 3-chloro-N-(4-{2-[(2-hydroxyethyl)amino]ethyl-1,3-thiazol-2-yl)-2-methylbenzenesulfonamide, N-[2-(2- { [(3-chloro-2-methylphenyl)sulfonyl] amino } -1,3-thiazo l-4-yl) ethyl]-N-i o ethylacetamide, 3-chloro-2-methyl-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl~benzenesulfonarnide, 3-chloro-N-{4-[2-(2-hydroxy-3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl~-2-methylbenzenesulfonamide, 2,4-dichloro-N- {4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, ~,4-dichloro-N- {4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl] -6-methylbenzenesulfonamide, N- {4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl) -2,4~6-2o trichlorobenzenesulfonamide, 4,5-dichloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl]-2-thienylsulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl,~-4-phenoxybenzenesulfonamide, 2s 3-fluoro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-y1 } b enzenesulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl~-5-(2-pyridyl)-2-thienylsulfonamide, 4-acetylamino-3-chloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-s o y1 ~ benzenesulfonamide, N-{4-[(3-oxo-4-morpholinyl)methyl]-1,3-thiazol-2-yl}-3-chloro-2-methylbenzenesulfonamide, N-{4-[3-(3-oxo-4-morpholinyl)propyl]-1,3-thiazol-2-yl}-3-chloro-2-methylbenzenesulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl},N-methyl-3-chloro-2-methylbenzenesulfonamide, s 3-chloro-2-methyl-N-{4-[2-(2-methyl-3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-(acetylamino)ethyl]-1,3-thiazol-2-yl}-3-chloro-2-methyl-benzenesulfonamide, 3-chloro-2-methyl-N- {4-[2-(4-(3-oxo-1,4-oxazepinyl))ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(1-pyrrolidonyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(1-(2-oxoimidazolinyl))ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, is 3-chloro-2-methyl-N-{4-[2-(1-(2-oxooxazolinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-{4-[2-(N-(2-furylcarbonyl),N-2-hydroxyethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, hydrochloride, 3-~chloro-2-methyl-N-{4-[2-(4-methyl-2-oxopiperazinyl)ethyl]-1,3-thiazol-2-2o yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(methylsulfonylamino)ethyl]-1,3-thiazol-2 yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(N-methyl,N-methylsulfonamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2s 3-chloro-2-methyl-N-{4-[2-(trifluoromethylsulfonylamino)ethyl]-1,3-thiazol-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(N-methyl,N-trifluoromethylsulfonamino)ethyl]-1,3-thiazol-2-yl} benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(4-(1-methylimidazolyl)sulfonylamino)ethyl]-1,3-3o thiazol-2-yl}benzenesulfonamide, 3-chloro-N- {4-[2-(N-(3-chloro-2-methylphenylsulfonyl),N-methylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, N-[4-(2-bromoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-chloroethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-{4-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-1,3-thiazol-2-yl~benzenesulfonamide, 3-chloro-N-{4-[2-(ethoxycarbonyl)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide.
In one aspect of the invention, the said method is a method for the treatment or prophylaxis of a medical condition involving delayed or impaired wound healing.
Examples of such medical conditions are diabetes, and conditions caused by treatment io with steroids, in particular glucocorticoids. The method according to the invention is also intended for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
The compounds referred to above may also be used in the manufacture of a medicament Is for promoting wound healing, e.g. for the treatment or prophylaxis of a medical condition involving delayed or impaired wound healing. Examples of such medical conditions are diabetes, and conditions caused by treatment with steroids, in particular glucocorticoids. The compounds referred to above may also be used for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure 2o ulcers.
The various terms used, separately and in combinations, in the above definition of the compounds having the general formula (I) will be explained.
2s The term "aryl" in the present description is intended to include aromatic rings (monocyclic or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph) and naphthyl, which optionally may be substituted by C1_6-alkyl. Examples of substituted aryl groups are benzyl and 2-methylphenyl.
3o The term "heteroaryl" means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, ~, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium. Examples of such heteroaryl rings are pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, s indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H 1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, fenazine and xanthene. Examples of monocyclic heteroaryl 1 o rings are pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, and tetrazole.
The term "heterocyclic" in the present description is intended to include unsaturated as 1 s well as partially and fully saturated mono-, bi- and tricyclic rings having from 4 to 14, preferably 4 to 10 ring atoms, such as, for example, the heteroaryl groups mentioned above as well as the corresponding partially saturated or fully saturated heterocyclic rings. Exemplary saturated heterocyclic rings are azetidine, pyrrolidine~
piperidine, piperazine, morpholine, thiomorpholine and 1,4-oxazepane.
C 1 _6-alkyl in the compound of formula (I) according to the present application, which may be straight or branched, is preferably C1_4-alkyl. Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, and isohexyl. For parts of the range "C1_6-alkyl" all subgroups thereof are contemplated 2s such as C1_s-alkyl, C1_4-alkyl, C2_6-alkyl, CZ_s-alkyl, CZ_4-alkyl, Ca_3-alkyl, Cs_s-alkyl, C4_ s-allcyl, etc.
C1-6-alkoxy, in the compound of formula (I) according to the present application may be straight or branched, is preferably C1_4-alkoxy. Exemplary alkoxy groups include 3o methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy, and isohexyloxy. For parts of the range "C1_6-alkoxy"
all subgroups thereof are contemplated such as C1_s-alkoxy, C1_4-alkoxy, CZ_6-alkoxy, CZ_s-alkoxy, C2_4-alkoxy, C2_3-alkoxy, C3_6-alkoxy, C4_s-alkoxy, etc.
C 1 _6-acyl, in the compound of formula (I) according to the present application may be saturated or unsaturated and is preferably C1_q.-acyl. Exemplary acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, butenoyl (e.g. 3-butenoyl), hexenoyl (e.g. 5-hexenoyl). For parts of the range "C1_6-acyl" all subgroups thereof are contemplated such as C1_5-acyl, C1_4-acyl, C2_~-acyl, C2_5-acyl, C2_4-acyl, C2_ 3-acyl, C3_~-acyl, C4_5-acyl, etc.
C2_~-alkenyl in the compound of formula (I) according to the present application, which Io ~ may be straight, branched or cyclic, is preferably C2_4-alkenyl.
Exemplary alkenyl groups include vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 1-hexenyl, and 2-hexenyl. For parts of the range "CZ_6-alkenyl" all subgroups thereof are contemplated such as CZ_5-alkenyl, C2_4-alkenyl, C2_3-alkenyl, C3_ 6-alkenyl, C4_5-alkenyl, etc.
is The term "halogen" in the present description is intended to include fluorine, chlorine, bromine and iodine.
The term "sulfanyl" in the present description means a thio group.
With the expression mono- or di-substituted is meant in the present description that the functionalities in question may be substituted with independently H, C1_6-acyl, Cl_s-alkenyl, C1_6-(cyclo)alkyl, aryl, pyridylmethyl, or heterocyclic rings e.g.
azetidine, pyrrolidine, piperidine, piperazine, morpholine and thiomorpholine, which heterocyclic 2s rings optionally may be substituted with C1_6-alkyl. With the expression "optionally mono- or disubstituted" is meant in the present description that the functionalities in question may also be substituted with independently hydrogen.
Combinations of substituents and variables envisioned by this invention are only those 3o that result in the formation of stable compounds. The term "stable", as used herein, referes to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic administration to a subject for the treatment of disease, 11-(3-HSD1 inhibition, 11-(3-HSD1-mediated disease).
The term "prodrug forms" in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gilman's, The Pharmacological basis of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs, p. 13-15).
to "Pharmaceutically acceptable" means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
is "Pharmaceutically acceptable salts" mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, malefic acid, malonic acid, 20 oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like. Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like.
2s The compounds of formula (I) can be prepared according to the methods described in WO 01/90090.
For use according to the invention, the compounds of formula (I) can preferably be topically administered. However, the compounds could also be administered by other 3o routes, for instance orally, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously.
EXAMPLES
Diabetic KKAy mice underwent surgery during anesthesia whereby a catheter was inserted in the jugularis vein. Oral treatment twice daily (200 mg/kg/day) with the 11 (3-HSD1 inhibitor BVT.2733 (3-Chloro-2-methyl-N- f 4-[2-oxo-2-(1-piperazinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide; the trifluoroacetate of this compound is disclosed to as Example 172A in WO 01/90090), or vehicle started 4-6 days later and continued for 3.5 days.
Advantageous effects on wound healing of the surgical wounds were observed during treatment. hi BVT.2733 treated mice, less complication were observed in and around is the wound area as compared to control mice. Examples of advantageous effects were less pus in the wound, as well as better wound strength. 5 ~ % of the vehicle treated animals showed complications during treatment period whereas complications were present in only 24 % of the BVT.2733 treated animals.
(a) Advantageous effects of 11(3-HSD1 inhibitors (e.g. BVT.2733) on wound healing are 2s confirmed in diabetic KKAY mice employing the excisional wound-healing model. 1 cm full-thickness wounds, including the panniculus carnosus muscle, are cut with a scalpel on the back of the mice. Mice are treated with BVT.2733 for 5 days. On day 2 and 9 of treatment wounds are harvested, embedded and sectioned. Histological staining of the sections with hematoxylin/eosin are made to determine degree of re-epithelialization so and immunostaining against the von Willebrand factor to determine revascularisation.
(b) Advantageous effects of 11 (3-HSD 1 inhibitors are confirmed in in vitro studies.
Proliferation of human keratinocytes and fibroblasts, which are important cell types in the wound healing process, are studied after incubation with the 11 [3-HSD 1 inhibitor.
s (c) Effects on wound healing after treatment with 11 (3-HSD1 inhibitors are also studied in wounds on explants from human breast skin. The proliferative effect of the substance and the effect on re-epithelialization are determined.
to REFERENCES
1. Ganong WF. Review of Medical Physiology. Eighteenth edition ed. Stamford, Connecticut: Appleton & Lange; 1997.
2. Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998;11 (6):277-85.
3. Diethelm AG. Surgical management of complications of steroid therapy. Ann Surg 1977;185(3):251-63.
4. Hutchinson TC, Swaniker HP. Wound diagnosis by quantitating cortisol in wound fluids. European patent application No. EP 0 902 288, published 17.03.1999.
RELATED APPLICATIONS
This application claims priority to Swedish application number 0301882-7, filed on June 25, 2003, the contents of which are incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to the use of chemical compounds for wound healing, said compounds acting on the human 11-(3-hydroxysteroid dehydrogenase type 1 enzyme (11 (3HSD1).
BACKGROUND ART
Cortisol performs a broad range of metabolic functions and other functions.
The multitude of glucocorticoid action is exemplified in patients with prolonged increase in plasma glucocorticoids, so called "Cushing's syndrome". Patients with Cushing's syndrome have prolonged increase in plasma glucocorticoids and exhibit impaired glucose tolerance, type 2 diabetes, central obesity, and osteoporosis. These patients also is have impaired wound healing and brittle skin (1).
Glucocorticoids have been shown to increase risk of infection and delay healing of open wounds (2). Patients treated with glucocorticoids have 2-5-fold increased risk of complications when undergoing surgery (3).
The European patent application No. EP 0902288 discloses a method for diagnosing the status of wound healing in a patient, comprising detecting cortisol levels in said wound.
The authors suggest that elevated levels of cortisol in wound fluid, relative to normal plasma levels in healthy individuals, correlates with large, non-healing wounds (4).
In humans, the 11 (3-HSD catalyzes the conversion of cortisol to cortisone, and vice versa. The parallel function of 11(3-HSD in rodents is the interconversion of _2_ corticosterone and 11-dehydrocorticosterone (5). Two isoenzymes of 11 (3-HSD, 11 [3-HSD 1 and 11 (3-HSD2, have been characterized, and differ from each other in function and tissue distribution (6). Like GR, 11 [3-HSD 1 is expressed in numerous tissues like liver, adipose tissue, adrenal cortex, gonads, lung, pituitary, brain, eye etc (7-9). The function of 11 (3-HSD 1 is to fine-tune local glucocorticoid action. 11 [3-HSD
activity has been shown in the skin of humans and rodents, in human fibroblasts and in rat skin pouch tissue (10-13).
Wound healing consists of serial events including inflammation, fibroblast proliferation, secretion of ground substances, collagen production, angiogenesis, wound contraction and epithelialization. It can be divided in three phases; inflammatory, proliferative and remodeling phase (reviewed in (2)).
In surgical patients, treatment with glucocorticoids increases risk of wound infection is and delay healing of open wounds. It has been shown in animal models that restraint stress slows down cutaneous wound healing and increases susceptibility to bacterial infection during wound healing. These effects were reversed by treatment with the glucocorticoid receptor antagonist RU486 (14, 15). Glucocorticoids produce these effects by suppressing inflammation, decrease wound strength, inlubit wound 2o contracture and delay epithelialization (2). Glucocorticoids influence wound healing by interfering with production or action of cytokines and growth factors like IGF, TGF-(3, EGF, KGF and PDGF (16-19). It has also been shown that glucocorticoids decrease collagen synthesis in rat and mouse skin in vivo and in rat and human fibroblasts (20).
2s WO 01/90090 discloses compounds of the formula (I) as defined hereinafter, which compounds inhibit the human 11(3-HSD1, and may be useful for treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders and immune disorders.
Other 11(3-HSD1 inhibitors axe disclosed in e.g. WO 01/90091; WO 01/90092; WO
01/90093; WO 01/90094; WO 03/044000; WO 03/044009; WO 03/043999; and 3o Swedish patent application No. SE 0301504-7, filed on May 21, 2003. WO
relates to glycyrrhetinic acid derivatives, progesterone and progesterone derivatives as 11 [3-HSD 1 inhibitors for wound healing. However, the use of the 11 [3-HSD 1 inhibitors according to the present invention for wound healing has not previously been disclosed.
DISCLOSURE OF THE INVENTION
It has surprisingly been found that the present inhibitors of 11 (3-HSD 1 are useful for the promotion of wound healing. Consequently, in a first aspect this invention provides a method for promoting wound healing, said method comprising administering to a mammal, including man, in need of wound healing an effective amount of an inhibitor of 11 (3-hydroxysteroid dehydrogenase type l, wherein the inhibitor of 11 (3-hydroxysteroid dehydrogenase type 1 is a compound of the formula (I):
to R~
T~S/N /N X~Y/R2 O \O
S
(I) wherein is T is an aryl ring or heteroaryl ring or aryl-C2-alkenyl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1_6-alkyl, optionally halogenated Cl_6-alkoxy, C1_6-alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono- or di-substituted, amide which is optionally mono- or di-substituted, aryloxy, arylsulfonyl, 2o arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings can further be optionally substituted in one or more positions independently of each other by C1_6-acyl, Cl_6-alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C1_6-alkyl, optionally halogenated C1_6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2-thienylmethylamino or ({[4-(2-ethoxy-2-2s oxoethyl)-1,3-thiazol-2-yl]amino]carbonyl);
Rl is hydrogen or C1_6-alkyl;
X is CHZ or CO;
Y is CH2, CO or a single bond;
B is hydrogen or C1_6-alkyl;
Rz is selected from C1_6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaxninomethyl, methylsulfonyloxymethyl, 3-oxo-4-morpholinolinylmethylene, C1_6-alkoxycarbonyl, and 5-methyl-1,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1_6-alkyl, optionally halogenated C1_6-alkylsulfonyl, C1_6-alkoxy, 2-methoxyethyl, 2-hydroxyethyl, l0 1-methylimidazolylsulfonyl, C1_6-acyl, cyclohexyhnethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl and C1_6-alkyl substituted with one or more aryl or heteroaryl, or NR3R4 represent together heterocyclic systems which can be imidazole, piperidine, pyrrolidine, piperazine, morpholine, oxazepine, oxazole, thiomorpholine, 1,1-Is dioxidothiomorpholine, 2-(3,4-dihydro-2(1H)isoquinolinyl), (1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems can be optionally substituted by CI_6-alkyl, Cl_6-acyl, hydroxy, oxo, t-butoxycarbonyl;
OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1_s-alkyl or form together morpholinyl;
2o R50, wherein RS is hydrogen, optionally halogenated C1_6-alkyl, aryl, heteroaryl, C1_6-aryl, C1_6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof.
2s It is preferred that:
T is selected from 5-chloro-1,3-dimethyl-1H-pyrazol-4-yl; 4-chloro-2,3,1-benzoxadiazolyl; 5-(dimethylamino)-1-naphthyl; 1-methylimidazol-4-yl; 1-naphthyl; 2-naphthyl; (E)-2-phenylethenyl; 8-quinolinyl;
3o thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3-isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1-methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl;
phenyl substituted with one or more of acetylamino, 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, 1,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5-bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro-2-cyanophenoxy, 4-chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ( f [4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2-furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl-1-piperazinyl, 4-methyl-1-piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4-morpholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3-pyridylmethylamino, 1-pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, io trifluoromethoxy, 4-trifluoromethoxyphenyl, and trifluoromethyl;
Rl is hydrogen or methyl;
X is CHZ or CO;
Y is CHZ, CO or a single bond;
B is hydrogen or methyl;
2o RZ is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-morpholinolinyhnethylene, ethoxycarbonyl, 5-methyl-1,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, 1,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexylmethyl, 2s ethyl, 2-furylcarbonyl, 2-furylmethyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl)ethyl, isopropyl, methoxy, 2-methoxyethyl, methyl, 4-(1-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, propyl, trifluoromethylsulfonyl; or NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2-(3,4-dihydro-2(1H)isoquinolinyl), (2R,6S)-2,6-dimethylmorpholinyl, (2R)-2,4-dimethyl-1-so piperazinyl, 2-hydroxy-3-oxomorpholinyl, imidazolyl, 2-methyl-3-oxomorpholinyl, 4-methyl-2-oxopiperazinyl, 4-methylpiperazinyl, morpholinyl, (1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomorpholinyl, 3-oxo-1,4-oxazepinyl, 2-oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomorpholinyl;
1,1-dioxido-thiomorpholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together morpholinyl;
R50, wherein RS is selected from acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, propionyl, 3-pyridinyl, and 2,2,2-trifluoroethyl.
The following compounds are especially preferred:
io ethyl (2-{[(2,4-dichloro-5-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-(2-[[(4-chlorophenyl)sulfonyl]amino]-1,3-thiazole-4-yl)acetate, ethyl 2-(2- { [ (4-chloro-2, 5-dimethylphenyl) sulfonyl] amino ~ -1,3-thiazol-yl)acetate, ~s ethyl2-(2-{[(2,4-difluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-(2-(((4-methylphenyl)sulfonyl)amino)-1,3-thiazol-4-yl)acetate, ethyl 2-(2-{[(2,5-dichloro-3-thienyl)sulfonyl]amino-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-(2- { [(3-chloro-2-methylphenyl)sulfonyl] amino }-1,3-thiazol-4-yl)acetate, 2o ethyl 2-{2-[([ l,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl) acetate, ethyl 2-(2- { [ (3 -bromophenyl) sulfonyl] amino ) -1, 3-thiazol-4-yl) acetate, ethyl (2-{[(4-nitrophenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-nitrophenyl)sulfonyl]amino-1,3-thiazol-4-yl)acetate, 2s ethyl (2-{[(3-methylphenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-chlorophenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-fluorophenyl)sulfonyl]amino)-1,3-thia,zol-4-yl)acetate, ethyl (2-{[(3-fluorophenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetate, ethyl {2-[(phenylsulfonyl)amino]-1,3-thiazol-4-yl~ acetate, 3o ethyl (2-{[(4-isopropylphenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetate, ethyl [2-({[3-({,[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl] amino} carbonyl)phenyl] sulfonyl~ amino)-1,3-thiazol-4-yl] acetate, ethyl [2-( f [4-( { [4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl] amino} carbonyl)phenyl]sulfonyl} amino)-1,3-thiazol-4-yl] acetate, ethyl (2- f [(2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-( f [2-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, s ethyl [2-(~[3-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-( f [4-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl 2-(2- f [(4-bromophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(2-nitrophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, to ethyl (2- f [(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(2,4-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(5-fluoro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-methoxy-4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, is ethyl (2- f [(3,5-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-( f [4-(3-chloro-2-cyanophenoxy)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, , ethyl (2-~[(3,4-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(4-butoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, 2o ethyl (2- f [(4-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[4-(acetylamino)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl ~2-[(8-quinolinylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2- f [(3,4-dirnethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-iodophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, 2s ethyl (2-{[(3-chloro-4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-( f [5-(dimethylamino)-1-naphthyl]sulfonyl}amino)-1,3-thiazol-4-yl] acetate, ethyl (2- f [(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(5-bromo-2-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(2,5-dimethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl ~2-[(2-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl f 2-[(mesitylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-~[(3-bromo-5-chloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, _g_ ethyl {2-[({5-[(benzoylamino)methyl]-2-thienyl}sulfonyl)amino]-1,3-thiazol-4-yl } acetate, ethyl {2-[({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl} sulfonyl)amino]-1,3-thiazol-4-yl} acetate, s ethyl (2-{[(4-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl {2-[({5-[2-(methylsulfanyl)-4-pyrimidinyl]-2-thienyl}sulfonyl)amino]-1,3-thiazol-4-yl} acetate, ethyl (2-{[(3-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,4,5-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, to ethyl [2-({[(E)-2-phenylethenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,3,4-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-2,5-difluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl]acetate, ethyl [2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,3-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, is ethyl (2-{[(2-bromophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4,5-dichloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[4-(phenylsulfonyl)-2-thienyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-({[5-(phenylsulfonyl)-2-thienyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,6-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, 2o ethyl (2-{[(2-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-({[4-(acetylamino)-3-chlorophenyl]sulfonyl}amino)-1,3-thiazol-4-y1] acetate, ethyl (2-{[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino}-1,3-thiazol-yl)acetate, 2s ethyl (2-{[(3-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-5-chloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl} acetate, ethyl (2-{[(2,5-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-methanesulfonylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, so ethyl (2-{[(2-methanesulfonylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-2-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-methyl-4-trifluoromethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4 yl)acetate, ethyl (2-{[(2,3,4-trifluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(4-chloro-2,3,1-benzoxadiazolyl)sulfonyl]amino}-1,3-thiazol-4 yl)acetate, ethyl (2- f [(2,4,6-trifluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, s ethyl (2-~[(S-carboxy-4-chloro-2-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(2-(5-chlorothienyl))sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(2-chloro-4-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-(5-(3-isoxazolo)thienyl))sulfonyl]amino}-1,3-thiazol-4-yl)acetate, to ethyl (2-~[(4-bromo-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(4-phenoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(4-chloro-2,6-dimethylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(2-methyl-4-trifluoromethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, is ethyl (2-~[(2,4-bis(trifluoromethyl)phenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ~ . .
ethyl 2-{2-[[(3-chloro-2-methylphenyl)sulfonyl](methyl)amino]-1,3-thiazol-4-yl} acetate, ethyl oxo(2- f [(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, 2o ethyl (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)(oxo)acetate, ethyl oxo(2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl {2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}(oxo)acetate, ethyl (2- f [(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-2s yl)(oxo)acetate, 2-(2- f [(4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, 2-(2- f [(2,5-dichloro-3-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, (2-{[(2-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, so isopropyl 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, phenyl 2-(2- { [(3-chloro-2-methylphenyl)sulfonyl] amino } -1, 3-thiazol-4-yl) acetate, methyl (2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl f 2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-5-methyl-1,3-thiazol-4-yl ] acetate, methyl (2-~[(4-chlorophenyl)sulfonyl]amino}-5-methyl-1,3-thiazol-4-yl)acetate, methyl (2- f [(3-chloro-2-methylphenyl)sulfonyl]amino]-5-methyl-1,3-thiazol-4 s yl)acetate, methyl [2-( f [4-(3-chloro-2-cyanophenoxy)phenyl]sulfonyl~amino)-5-methyl-1,3-thiazol-4-yl]acetate, methyl (5-methyl-2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl (5-methyl-2- f [(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-1 o yl)acetate, methyl (2- f [(2,4-dichloro-6-methylphenyl)sulfonyl]amino]-5-methyl-1,3-thiazo1-4-yl)acetate, N-(2-methoxyethyl)-2-(2- f [(4-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)acetamide, Is 2-(2-~[(2,S-dichloro-3-thienyl)sulfonyl]amino)-1,3-thia,zol-4-yl)-N-methylacetamide, N-(1,3-benzodioxol-5-ylmethyl)-2-~2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl] acetamide, N-(2-furylmethyl)-2- f2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, 20 2-(2- f [(2,4-difluorophenyl)sulfonyl]amino-1,3-thiazol-4-yl)-N-ethylacetamide, N-isopropyl-2- f 2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl} acetamide, N-[2-( 1 H-indo l-3-yl) ethyl]-2- ~2-[( 1-naphthylsulfonyl) amino]-1, 3-thi azol-4-yl] acetamide, N-(cyclohexylmethyl)-2- f 2-[(phenylsulfonyl)amino]-1,3-thiazol-4-yl}
acetamide, 2s 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)-N-methylacetamide, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)-N-ethylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)-N-3o phenylacetamide, 2-(2-~[(4-chlorophenyl)sulfonyl]amino]-1,3-thiazol-4-yl)-N-(2-furylmethyl)acetamide, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)acetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-diethylacetamide, 2- f 2-[([ l,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N,N-diethylacetamide, s N,N-diethyl-2-(2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2- ~ [(2,4-dichloro-6-methylphenyl)sulfonyl] amino } -1, 3-thiazol-4-yl)-N,N-diethylacetamide, N,N-diethyl-2-(2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, l0 2-f2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N,N-diisopropylacetamide, N,N-diisopropyl-2-(2- f [(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2- ~ [(2,4-dichloro-6-methylphenyl) sulfonyl] amino } -1,3-thiazol-4-yl)-N,N-1 s diisopropylacetamide, N,N-diisopropyl-2-(2- { [(2,4,6-trichlorophenyl)sulfonyl] amino}-1,3-thiazol-4-yl)acetamide, 2-(2- ~ [(3-chloro-2-methylphenyl) sulfonyl] amino } -1, 3-thiazol-4-yl)-N,N-diisopropylacetamide, 20 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-dipropylacetamide, N-benzyl-2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethylacetamide, 2-(2-~[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-2s dimethylacetamide, 3-chloro-N- f 4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-methyl-N-phenylacetamide, so 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-isopropyl-N-methylacetamide, 2- f 2-[([l,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N-isopropyl-N-methylacetamide, N-ethyl-N-methyl-2-(2- f [(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2- f [(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethyl-N-methylacetamide, s N-ethyl-N-methyl-2-(2-~[(4-propylphenyl)sulfonyl]amino)-1,3-thiazol-4-yl)acetamide, 2- f 2-[([ 1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl)-N-ethyl-N-methylacetamide, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethyl-N-t o methylacetamide, 3-chloro-2-methyl-N- f 4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,3-thiazol-2-yl)benzenesulfonamide, 3-chloro-2-methyl-N- {4-[2-oxo-2-( 1-piperidinyl)ethyl]-1,3-thiazol-2-yl)benzenesulfonamide, is N-~4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl)[l,l'-biphenyl]-4-sulfonamide, N-~4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide, 2,4-dichloro-6-methyl-N- f 4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-2o yl}benzenesulfonamide, 2,4,6-trichloro-N- f 4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl)benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl)benzenesulfonamide, 2s 2,4,6-trichloro-N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl)benzenesulfonamide, 2,4-dichloro-6-methyl-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl} [ 1,1'-biphenyl]-4-3o sulfonamide, N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl)-4-propylbenzenesulfonamide, 2,4-dichloro-N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-chloro-2,6-dimethyl-N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl } b enzenesulfonamide, s N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-phenoxybenzenesulfonamide, 2-methyl-N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-(trifluoromethoxy)benzenesulfonamide, N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-2,4-bis(trifluoromethyl)benzenesulfonamide, 4-bromo-2-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(2-furyl)-N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl} benzenesulfonamide, is 4-(5-fluoro-2-methoxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl} benzenesulfonamide, 4-(5-methyl-2-thienyl)-N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-acetylphenyl)-N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-2o yl}benzenesulfonamide, 4-(4-trifluoromethoxyphenyl)-N-~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3,4-dichlorophenyl)-N- ~4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl} benzenesulfonamide, 2s 4-(3,4-methylenedioxyphenyl)-N- f 4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(5-chloro-2-thienyl)-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl } benzenesulfonamide, 4-(4-pyridyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-y1 } b enzenesulfonamide, 4-(3-acetylaminophenyl)-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-thienyl)-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(2-thienyl)-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, s 4-(4-carboxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methylsulfanylphenyl)-N- {4-[2-(4-morpholinyl)-2-oxo ethyl]-1,3-thi azol-yl}benzenesulfonamide, 4-(3,5-bis(trifluoromethyl)phenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-chlorophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazo1-2-y1 } b enzenesulfonamide, 4-(3-nitrophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, is 4-(2-benzofuryl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(1-pyrrolidino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methyl-1-piperidino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-2o y1 } benzenesulfonasnide, 4-(benzeneamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(benzylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2s 4-(2-thienylmethylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-morpholinyl)-N- {4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methyl-1-piperazinyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-3o yl}benzenesulfonamide, 4-(3-pyridylmethylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4-dichloro-6-methyl-N- ~5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N- ~5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl] [ 1,1'-biphenyl]-4-sulfonamide, s 2,4,6-trichloro-N- f 5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-~5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-(4- f 2-[(2R,6S)-2,6-dimethylmorpholinyl]-2-oxoethyl]-1,3-thiazol-2-1 o yl)-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-(4- f2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]kept-5-yl]-2-oxoethyl}-1,3-thiazol-2-yl)benzenesulfonamide, 3-chloro-2-methyl-N- f 4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, is N-f4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}[1,1'-biphenyl]-4-sulfonamide, N-~4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl]-4-propylbenzenesulfonamide, 2,4-dichloro-6-methyl-N- f 4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-2o yl]benzenesulfonamide, 2,4,6-trichloro-N-~4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N- ~4-[2-( 1,1-dioxido-4-thiomorpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl} -4-propylbenzenesulfonamide, 2s tert-butyl 4-[(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)acetyl]-1-piperazinecarboxylate, 4-acetyl-(4-[(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetyl])-1-piperazine, 4-[(2-~[(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)acetyl]-1-3o piperazine trifluoroacetate, 3-chloro-2-methyl-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide hydrochloride, 2-methyl-N- f 4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-(trifluoromethoxy)benzenesulfonamide, 2,4-dichloro-6-methyl-N- {4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, s 2,4-dichloro-N-~4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-(4- f 2-[(2R)-2,4-dimethylpiperazinyl]-2-oxoethyl}-1,3-thiazol-2-yl)-2-methylbenzenesulfonamide, 2-(2- ~ [(3-chloro-2-methylphenyl)sulfonyl] amino}-1,3-thiazol-4-yl)-N-methoxy-lo N-methylacetamide, 3-chloro-2-methyl-N-[4-(2-oxopentyl)-1,3-thiazol-2-yl]benzenesulfonamide, 4-chloro-N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]benzenesulfonamide, 3-chloro-N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-ethoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, Is 3-chloro-N-[4-(2-isopropoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, N- ~4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-yl } -3-chloro-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-methoxyethyl)-1,3-thiazol-2-yl]-2-riiethylbenzenesulfonamide, ao 3-chloro-N-{4-[2-(2-fluoroethoxy)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N- f 4-[2-(2,2,2-trifluoroethoxy)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N- f 4-[2-(2-pyridinylsulfanyl)ethyl]-1,3-thiazol-2-2s yl}benzenesulfonamide, 3-chloro-2-methyl-N- f 4-[2-(3-pyridinyloxy)ethyl]-1,3-thiazol-2-yl } benzenesulfonamide, 3-chloro-2-methyl-N- f 4-[2-methylsalicylethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2-(2- ~ [(3-chloro-2-methylphenyl)sulfonyl] amino } -1,3-thiazol-4-yl)ethyl methanesulfonate, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl acetate, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl propionate, 2-(2-~[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl 2-methylpropanoate, s 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl2-furoate, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl benzoate, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl 4-1 o morpholinecarboxylate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl diethylcarbamate, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl ethylcarbamate, is N-[4-(2-azidoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide, N-[4-(2-aminoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide hydrochloride, 4-chloro-N-~4-[2-(diethylamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 20 3-chloro-N-{4-[2-(diethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide hydrochloride, 3-chloro-N-{4-[2-(1-imidazolyl)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide hydrochloride, 3-chloro-2-methyl-N-~4-[2-(4-methyl-1-piperazinyl)ethyl]-1,3-thiazol-2-2s yl}benzenesulfonamide dihydrochloride, 3-chloro-2-methyl-N-~4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 3-chloro-2-methyl-N-{4-[(4-morpholinyl)methyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 30 2,4,6-trichloro-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2,4-dichloro-N-~4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2,4-dichloro-6-methyl-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2 yl}benzenesulfonamide hydrochloride, N- {4-[2-(4- morpholinyl)ethyl]-1,3-thiazol-2-yl~ -4-propylbenzenesulfonamide hydrochloride, s 3-chloro-N-{4-[2-(ethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 3-chloro-N-(4-{2-[(2-hydroxyethyl)amino]ethyl-1,3-thiazol-2-yl)-2-methylbenzenesulfonamide, N-[2-(2- { [(3-chloro-2-methylphenyl)sulfonyl] amino } -1,3-thiazo l-4-yl) ethyl]-N-i o ethylacetamide, 3-chloro-2-methyl-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl~benzenesulfonarnide, 3-chloro-N-{4-[2-(2-hydroxy-3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl~-2-methylbenzenesulfonamide, 2,4-dichloro-N- {4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, ~,4-dichloro-N- {4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl] -6-methylbenzenesulfonamide, N- {4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl) -2,4~6-2o trichlorobenzenesulfonamide, 4,5-dichloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl]-2-thienylsulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl,~-4-phenoxybenzenesulfonamide, 2s 3-fluoro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-y1 } b enzenesulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl~-5-(2-pyridyl)-2-thienylsulfonamide, 4-acetylamino-3-chloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-s o y1 ~ benzenesulfonamide, N-{4-[(3-oxo-4-morpholinyl)methyl]-1,3-thiazol-2-yl}-3-chloro-2-methylbenzenesulfonamide, N-{4-[3-(3-oxo-4-morpholinyl)propyl]-1,3-thiazol-2-yl}-3-chloro-2-methylbenzenesulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl},N-methyl-3-chloro-2-methylbenzenesulfonamide, s 3-chloro-2-methyl-N-{4-[2-(2-methyl-3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-(acetylamino)ethyl]-1,3-thiazol-2-yl}-3-chloro-2-methyl-benzenesulfonamide, 3-chloro-2-methyl-N- {4-[2-(4-(3-oxo-1,4-oxazepinyl))ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(1-pyrrolidonyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(1-(2-oxoimidazolinyl))ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, is 3-chloro-2-methyl-N-{4-[2-(1-(2-oxooxazolinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-{4-[2-(N-(2-furylcarbonyl),N-2-hydroxyethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, hydrochloride, 3-~chloro-2-methyl-N-{4-[2-(4-methyl-2-oxopiperazinyl)ethyl]-1,3-thiazol-2-2o yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(methylsulfonylamino)ethyl]-1,3-thiazol-2 yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(N-methyl,N-methylsulfonamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2s 3-chloro-2-methyl-N-{4-[2-(trifluoromethylsulfonylamino)ethyl]-1,3-thiazol-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(N-methyl,N-trifluoromethylsulfonamino)ethyl]-1,3-thiazol-2-yl} benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(4-(1-methylimidazolyl)sulfonylamino)ethyl]-1,3-3o thiazol-2-yl}benzenesulfonamide, 3-chloro-N- {4-[2-(N-(3-chloro-2-methylphenylsulfonyl),N-methylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, N-[4-(2-bromoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-chloroethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-{4-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-1,3-thiazol-2-yl~benzenesulfonamide, 3-chloro-N-{4-[2-(ethoxycarbonyl)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide.
In one aspect of the invention, the said method is a method for the treatment or prophylaxis of a medical condition involving delayed or impaired wound healing.
Examples of such medical conditions are diabetes, and conditions caused by treatment io with steroids, in particular glucocorticoids. The method according to the invention is also intended for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
The compounds referred to above may also be used in the manufacture of a medicament Is for promoting wound healing, e.g. for the treatment or prophylaxis of a medical condition involving delayed or impaired wound healing. Examples of such medical conditions are diabetes, and conditions caused by treatment with steroids, in particular glucocorticoids. The compounds referred to above may also be used for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure 2o ulcers.
The various terms used, separately and in combinations, in the above definition of the compounds having the general formula (I) will be explained.
2s The term "aryl" in the present description is intended to include aromatic rings (monocyclic or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph) and naphthyl, which optionally may be substituted by C1_6-alkyl. Examples of substituted aryl groups are benzyl and 2-methylphenyl.
3o The term "heteroaryl" means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, ~, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium. Examples of such heteroaryl rings are pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, s indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H 1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, fenazine and xanthene. Examples of monocyclic heteroaryl 1 o rings are pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, and tetrazole.
The term "heterocyclic" in the present description is intended to include unsaturated as 1 s well as partially and fully saturated mono-, bi- and tricyclic rings having from 4 to 14, preferably 4 to 10 ring atoms, such as, for example, the heteroaryl groups mentioned above as well as the corresponding partially saturated or fully saturated heterocyclic rings. Exemplary saturated heterocyclic rings are azetidine, pyrrolidine~
piperidine, piperazine, morpholine, thiomorpholine and 1,4-oxazepane.
C 1 _6-alkyl in the compound of formula (I) according to the present application, which may be straight or branched, is preferably C1_4-alkyl. Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, and isohexyl. For parts of the range "C1_6-alkyl" all subgroups thereof are contemplated 2s such as C1_s-alkyl, C1_4-alkyl, C2_6-alkyl, CZ_s-alkyl, CZ_4-alkyl, Ca_3-alkyl, Cs_s-alkyl, C4_ s-allcyl, etc.
C1-6-alkoxy, in the compound of formula (I) according to the present application may be straight or branched, is preferably C1_4-alkoxy. Exemplary alkoxy groups include 3o methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy, and isohexyloxy. For parts of the range "C1_6-alkoxy"
all subgroups thereof are contemplated such as C1_s-alkoxy, C1_4-alkoxy, CZ_6-alkoxy, CZ_s-alkoxy, C2_4-alkoxy, C2_3-alkoxy, C3_6-alkoxy, C4_s-alkoxy, etc.
C 1 _6-acyl, in the compound of formula (I) according to the present application may be saturated or unsaturated and is preferably C1_q.-acyl. Exemplary acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, butenoyl (e.g. 3-butenoyl), hexenoyl (e.g. 5-hexenoyl). For parts of the range "C1_6-acyl" all subgroups thereof are contemplated such as C1_5-acyl, C1_4-acyl, C2_~-acyl, C2_5-acyl, C2_4-acyl, C2_ 3-acyl, C3_~-acyl, C4_5-acyl, etc.
C2_~-alkenyl in the compound of formula (I) according to the present application, which Io ~ may be straight, branched or cyclic, is preferably C2_4-alkenyl.
Exemplary alkenyl groups include vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 1-hexenyl, and 2-hexenyl. For parts of the range "CZ_6-alkenyl" all subgroups thereof are contemplated such as CZ_5-alkenyl, C2_4-alkenyl, C2_3-alkenyl, C3_ 6-alkenyl, C4_5-alkenyl, etc.
is The term "halogen" in the present description is intended to include fluorine, chlorine, bromine and iodine.
The term "sulfanyl" in the present description means a thio group.
With the expression mono- or di-substituted is meant in the present description that the functionalities in question may be substituted with independently H, C1_6-acyl, Cl_s-alkenyl, C1_6-(cyclo)alkyl, aryl, pyridylmethyl, or heterocyclic rings e.g.
azetidine, pyrrolidine, piperidine, piperazine, morpholine and thiomorpholine, which heterocyclic 2s rings optionally may be substituted with C1_6-alkyl. With the expression "optionally mono- or disubstituted" is meant in the present description that the functionalities in question may also be substituted with independently hydrogen.
Combinations of substituents and variables envisioned by this invention are only those 3o that result in the formation of stable compounds. The term "stable", as used herein, referes to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic administration to a subject for the treatment of disease, 11-(3-HSD1 inhibition, 11-(3-HSD1-mediated disease).
The term "prodrug forms" in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gilman's, The Pharmacological basis of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs, p. 13-15).
to "Pharmaceutically acceptable" means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
is "Pharmaceutically acceptable salts" mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, malefic acid, malonic acid, 20 oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like. Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like.
2s The compounds of formula (I) can be prepared according to the methods described in WO 01/90090.
For use according to the invention, the compounds of formula (I) can preferably be topically administered. However, the compounds could also be administered by other 3o routes, for instance orally, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously.
EXAMPLES
Diabetic KKAy mice underwent surgery during anesthesia whereby a catheter was inserted in the jugularis vein. Oral treatment twice daily (200 mg/kg/day) with the 11 (3-HSD1 inhibitor BVT.2733 (3-Chloro-2-methyl-N- f 4-[2-oxo-2-(1-piperazinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide; the trifluoroacetate of this compound is disclosed to as Example 172A in WO 01/90090), or vehicle started 4-6 days later and continued for 3.5 days.
Advantageous effects on wound healing of the surgical wounds were observed during treatment. hi BVT.2733 treated mice, less complication were observed in and around is the wound area as compared to control mice. Examples of advantageous effects were less pus in the wound, as well as better wound strength. 5 ~ % of the vehicle treated animals showed complications during treatment period whereas complications were present in only 24 % of the BVT.2733 treated animals.
(a) Advantageous effects of 11(3-HSD1 inhibitors (e.g. BVT.2733) on wound healing are 2s confirmed in diabetic KKAY mice employing the excisional wound-healing model. 1 cm full-thickness wounds, including the panniculus carnosus muscle, are cut with a scalpel on the back of the mice. Mice are treated with BVT.2733 for 5 days. On day 2 and 9 of treatment wounds are harvested, embedded and sectioned. Histological staining of the sections with hematoxylin/eosin are made to determine degree of re-epithelialization so and immunostaining against the von Willebrand factor to determine revascularisation.
(b) Advantageous effects of 11 (3-HSD 1 inhibitors are confirmed in in vitro studies.
Proliferation of human keratinocytes and fibroblasts, which are important cell types in the wound healing process, are studied after incubation with the 11 [3-HSD 1 inhibitor.
s (c) Effects on wound healing after treatment with 11 (3-HSD1 inhibitors are also studied in wounds on explants from human breast skin. The proliferative effect of the substance and the effect on re-epithelialization are determined.
to REFERENCES
1. Ganong WF. Review of Medical Physiology. Eighteenth edition ed. Stamford, Connecticut: Appleton & Lange; 1997.
2. Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998;11 (6):277-85.
3. Diethelm AG. Surgical management of complications of steroid therapy. Ann Surg 1977;185(3):251-63.
4. Hutchinson TC, Swaniker HP. Wound diagnosis by quantitating cortisol in wound fluids. European patent application No. EP 0 902 288, published 17.03.1999.
5. Frey FJ, Escher G, Frey BM. Pharmacology of 11 beta-hydroxysteroid dehydrogenase. Steroids 1994;59(2):74-9.
6. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme.
Mol Cell Endocrinol 1994;105(2):R11-7.
Mol Cell Endocrinol 1994;105(2):R11-7.
7. Monder C, White PC. 11 beta-hydroxysteroid dehydrogenase. Vitam Horm .
1993;47:187-271.
1993;47:187-271.
8. Stewart PM, Krozowski ZS. 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 1999;57:249-324.
9. Stokes J, Noble J, Brett L, Phillips C, Seckl JR, O'Brien C, et al.
Distribution of glucocorticoid and mineralocorticoid receptors and llbeta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Invest Ophthalmol Vis Sci 2000;41 (7):1629-38.
Distribution of glucocorticoid and mineralocorticoid receptors and llbeta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Invest Ophthalmol Vis Sci 2000;41 (7):1629-38.
10. Hammami MM, Siiteri PK. Regulation of 11 beta-hydroxysteroid dehydrogenase activity in human skin fibroblasts: enzymatic modulation of glucocorticoid action. J Clin Endocrinol Metab 1991;73(2):326-34.
11. Cooper MS, Moore J, Filer A, Buckley CD, Hewison M, Stewart PM. 1 lbeta-hydroxysteroid dehydrogenase in human fibroblasts: expression and regulation depends on tissue of origin. ENDO 2003 Abstracts 2003.
12. Teelucksingh S, Mackie AD, Burt D, Mclntyre MA, Brett L, Edwards CR.
Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet 1990;335(8697):1060-3.
Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet 1990;335(8697):1060-3.
13. Slight SH, Chilakamarri VK, Nasr S, Dhalla AK, Ramires FJ, Sun Y, et al.
Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation. Mol Cell Biochem 1998;189(1-2):47-54.
Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation. Mol Cell Biochem 1998;189(1-2):47-54.
14. Mercado AM, Quan N, Padgett DA, Sheridan JF, Marucha PT. Restraint stress alters the expression of interleukin-1 and keratinocyte growth factor at the wound site:
an in situ hybridization study. J Neuroimmunol 2002;129(1-2):74-83. .
an in situ hybridization study. J Neuroimmunol 2002;129(1-2):74-83. .
15. Rojas IG, Padgett DA, Sheridan JF, Marucha PT. Stress-induced susceptibility to bacterial infection during cutaneous wound healing. Brain Behav Immun 2002;16(1):74-84.
16. Beer HD, Fassler R, Werner S. Glucocorticoid-regulated gene expression during cutaneous wound repair. Vitam Horm 2000;59:217-39.
17. Hamon GA, Hunt TK, Spencer EM. In vivo effects of systemic insulin-like growth factor-I alone and complexed with insulin-like growth factor binding protein-3 on corticosteroid suppressed wounds. Growth Regul 1993;3(1):53-6.
18. Laato M, Heino J, Kahari VM, Niinikoski J, Gerdin B. Epidermal growth factor (EGF) prevents methylprednisolone-induced inhibition of wound healing. J Surg Res 1989;47(4):354-9.
19. Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Gramates P, Deuel TF.
Transforming growth factor beta reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophages by platelet-derived growth factor.
Proc Natl Acad Sci U S A 1989;86(7):2229-33.
_27_ 20. Oishi Y, Fu ZW, Ohnuki Y, Kato H, Noguchi T. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment:
effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 2002;147(5):859-68.
Transforming growth factor beta reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophages by platelet-derived growth factor.
Proc Natl Acad Sci U S A 1989;86(7):2229-33.
_27_ 20. Oishi Y, Fu ZW, Ohnuki Y, Kato H, Noguchi T. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment:
effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 2002;147(5):859-68.
Claims (12)
1. A method for promoting wound healing, said method comprising administering to a mammal, including man, in need of wound healing an effective amount of an inhibitor of 11-.beta.-hydroxysteroid dehydrogenase type 1, wherein the inhibitor of 11-.beta.-hydroxysteroid dehydrogenase type 1 is a compound of the formula (I):
wherein T is an aryl ring or heteroaryl ring or aryl-C2-alkenyl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, C1-6-alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono- or di-substituted, amide which is optionally mono- or di-substituted, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings can further be optionally substituted in one or more positions independently of each other by C1-6-acyl, C1-6-alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2-thienylmethylamino or ({[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino} carbonyl);
R1 is hydrogen or C1-6-alkyl;
X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen or C1-6-alkyl;
R2 is selected from C1-6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl,
wherein T is an aryl ring or heteroaryl ring or aryl-C2-alkenyl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, C1-6-alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono- or di-substituted, amide which is optionally mono- or di-substituted, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings can further be optionally substituted in one or more positions independently of each other by C1-6-acyl, C1-6-alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2-thienylmethylamino or ({[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino} carbonyl);
R1 is hydrogen or C1-6-alkyl;
X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen or C1-6-alkyl;
R2 is selected from C1-6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl,
2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4-morpholinolinylmethylene, C1-6-alkoxycarbonyl, and 5-methyl-1,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6-alkyl, optionally halogenated C1-6-alkylsulfonyl, C1-6-alkoxy, 2-methoxyethyl, 2-hydroxyethyl, 1-methylimidazolylsulfonyl, C1-6-acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl and C1-6-alkyl substituted with one or more aryl or heteroaryl, or NR3R4 represent together heterocyclic systems which can be imidazole, piperidine, pyrrolidine, piperazine, morpholine, oxazepine, oxazole, thiomorpholine, 1,1-dioxidothiomorpholine, 2-(3,4-dihydro-2(1H)isoquinolinyl), (1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems can be optionally substituted by C1-6-alkyl, C1-6-acyl, hydroxy, oxo, t-butoxycarbonyl;
OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-alkyl or form together morpholinyl;
R5O, wherein R5 is hydrogen, optionally halogenated C1-6-alkyl, aryl, heteroaryl, C1-6-acyl, C1-6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof.
2. The method according to claim 1, wherein T is selected from 5-chloro-1,3-dimethyl-1H-pyrazol-4-yl; 4-chloro-2,3,1-benzoxadiazolyl; 5-(dimethylamino)-1-naphthyl; 1-methylimidazol-4-yl; 1-naphthyl; 2-naphthyl; (E)-2-phenylethenyl; 8-quinolinyl;
thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3-isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1-methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl;
phenyl substituted with one or more of acetylamino, 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, 1,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino,
NR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6-alkyl, optionally halogenated C1-6-alkylsulfonyl, C1-6-alkoxy, 2-methoxyethyl, 2-hydroxyethyl, 1-methylimidazolylsulfonyl, C1-6-acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl and C1-6-alkyl substituted with one or more aryl or heteroaryl, or NR3R4 represent together heterocyclic systems which can be imidazole, piperidine, pyrrolidine, piperazine, morpholine, oxazepine, oxazole, thiomorpholine, 1,1-dioxidothiomorpholine, 2-(3,4-dihydro-2(1H)isoquinolinyl), (1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems can be optionally substituted by C1-6-alkyl, C1-6-acyl, hydroxy, oxo, t-butoxycarbonyl;
OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-alkyl or form together morpholinyl;
R5O, wherein R5 is hydrogen, optionally halogenated C1-6-alkyl, aryl, heteroaryl, C1-6-acyl, C1-6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof.
2. The method according to claim 1, wherein T is selected from 5-chloro-1,3-dimethyl-1H-pyrazol-4-yl; 4-chloro-2,3,1-benzoxadiazolyl; 5-(dimethylamino)-1-naphthyl; 1-methylimidazol-4-yl; 1-naphthyl; 2-naphthyl; (E)-2-phenylethenyl; 8-quinolinyl;
thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3-isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1-methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl;
phenyl substituted with one or more of acetylamino, 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, 1,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino,
3,5-bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro-2-cyanophenoxy, 4-chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2-furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl,
4-methyl-1-piperazinyl, 4-methyl-1-piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4-morpholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3-pyridylmethylamino, 1-pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, and trifluoromethyl;
R1 is hydrogen or methyl;
X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen or methyl;
R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-morpholinolinylmethylene, ethoxycarbonyl, 5-methyl-1,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, 1,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexylmethyl, ethyl, 2-furylcarbonyl, 2-furylmethyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl)ethyl, isopropyl, methoxy, 2-methoxyethyl, methyl, 4-(1-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, propyl, trifluoromethylsulfonyl; or NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2-(3,4-dihydro-2(1H)isoquinolinyl), (2R,6S)-2,6-dimethylmorpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxy-3-oxomorpholinyl, imidazolyl, 2-methyl-3-oxomorpholinyl, 4-methyl-2-oxopiperazinyl, 4-methylpiperazinyl, morpholinyl, (1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomorpholinyl, 3-oxo-1,4-oxazepinyl, 2-oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomorpholinyl;
1,1-dioxido-thiomorpholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together morpholinyl;
R5O, wherein R5 is selected from acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, propionyl, 3-pyridinyl, and 2,2,2-trifluoroethyl.
3. The method according to any one of claims 1 or 2, wherein the compound is selected from:
ethyl (2-{[(2,4-dichloro-5-methylphenyl)sulfonyl]amino}1,3-thiazol-4-yl)acetate, ethyl 2-(2-[[(4-chlorophenyl)sulfonyl]amino]-1,3-thiazole-4-yl)acetate, ethyl 2-(2-{[(4-chloro-2,5-dimethylphenyl)sulfonyl]amino-1,3-thiazol-4-yl)acetate, ethyl 2-(2-{[(2,4-difluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-(2-(((4-methylphenyl)sulfonyl)amino)-1,3-thiazol-4-yl)acetate, ethyl 2-(2-{[(2,5-dichloro-3-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-{2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl 2-(2-{[(3-bromophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-nitrophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-nitrophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl {2-[(phenylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(4-isopropylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[3-({[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl] amino}carbonyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-({[4-({[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino}carbonyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[2-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-({[3-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-({[4-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl 2-(2-{[(4-bromophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-nitrophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,4-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(5-fluoro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-methoxy-4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3,5-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[4-(3-chloro-2-cyanophenoxy)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(3,4-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-butoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[4-(acetylamino)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl {2-[(8-quinolinylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(3,4-dimethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-iodophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-chloro-4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[5-(dimethylamino)-1-naphthyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(5-bromo-2-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,5-dimethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl {2-[(2-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl {2-[(mesitylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(3-bromo-5-chloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl {2-[({5-[(benzoylamino)methyl]-2-thienyl}sulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl {2-[({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl}sulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(4-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl{2-[({5-[2-(methylsulfanyl)-4-pyrimidinyl]-2-thienyl}sulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(3-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,4,5-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[(E)-2-phenylethenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,3,4-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-2,5-difluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl]acetate, ethyl [2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,3-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-bromophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4,5-dichloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[4-(phenylsulfonyl)-2-thienyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-({[5-(phenylsulfonyl)-2-thienyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,6-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-({[4-(acetylamino)-3-chlorophenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino}-1,3-thiazol-yl)acetate, ethyl (2-{[(3-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-5-chloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(2,5-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-methanesulfonylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-methanesulfonylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-2-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-methyl-4-trifluoromethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4 yl)acetate, ethyl (2-{[(2,3,4-trifluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2{[(4-chloro-2,3,1-benzoxadiazolyl)sulfonyl]amino}-1,3-thiazol-4 yl)acetate, ethyl (2-{[(2,4,6-trifluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(5-carboxy-4-chloro-2-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-(5-chlorothienyl))sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-chloro-4-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-(5-(3-isoxazolo)thienyl))sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ZZZZ ethyl (2-{[(4-phenoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(4-chloro-2,6-dimethylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(2-methyl-4-trifluoromethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(2,4-bis(trifluoromethyl)phenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2- {2-[ [(3-chloro-2-methylphenyl)sulfonyl] (methyl)amino]-1,3-thiazol-4-yl} acetate, ethyl oxo(2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1;3-thiazol-4-. yl)(oxo)acetate, , ethyl oxo(2-~[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl ~2-[([l,l'~ biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}(oxo)acetate, ethyl (2-~[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)(oxo)acetate, 2-(2-~[(4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, 2-(2- f [(2,5-dichloro-3-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, (2-{[(2-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, isopropyl 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, phenyl 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl (2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl ~2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-5-methyl-1,3-thiazol-4-y1 } acetate, methyl (2-~[(4-chlorophenyl)sulfonyl]amino}-5-methyl-1,3-thiazol-4-yl)acetate, methyl (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-5-methyl-1,3-thiazol-4-yl)acetate, methyl [2-({[4-(3-chloro-2-cyanophenoxy)phenyl]sulfonyl}amino)-5-methyl-1,3-thiazol-4-yl] acetate, methyl (5-methyl-2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl (5-methyl-2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl (2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-5-methyl-1,3-thiazol-4-yl)acetate, N-(2-methoxyethyl)-2-(2-{[(4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(2,5-dichloro-3-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-methylacetamide, N-(1,3-benzodioxol-5-ylmethyl)-2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, N-(2-furylmethyl)-2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, 2-(2-{[(2,4-difluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethylacetamide, N-isopropyl-2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, N-[2-(1H-indol-3-yl)ethyl]-2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, N-(cyclohexylmethyl)-2-{2-[(phenylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-methylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-phenylacetamide, 2-(2-{[(4-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-(2-furylmethyl)acetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-diethylacetamide, 2-{2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N,N-diethylacetamide, N,N-diethyl-2-(2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-diethylacetamide, N,N-diethyl-2-(2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-{2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N,N-diisopropylacetamide, N,N-diisopropyl-2-(2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-diisopropylacetamide, N,N-diisopropyl-2-(2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-diisopropylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-dipropylacetamide, N-benzyl-2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-dimethylacetamide, 3-chloro-N-{4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-methyl-N-phenylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-isopropyl-N-methylacetamide, 2-{2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N-isopropyl-N-methylacetamide, N-ethyl-N-methyl-2-(2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethyl-N-methylacetamide, N-ethyl-N-methyl-2-(2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-{2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N-ethyl-N-methylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethyl-N-methylacetamide, 3-chloro-2-methyl-N-{4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}[1,1'-biphenyl]-4-sulfonamide, N-{4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide;
2,4-dichloro-6-methyl-N-{4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4,6-trichloro-N-{4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4,6-trichloro-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4-dichloro-6-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}[1,1'-biphenyl]-4-sulfonamide, N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide, 2,4-dichloro-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-chloro-2,6-dimethyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide, N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-phenoxybenzenesulfonamide, 2-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-(trifluoromethoxy)benzenesulfonamide, N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-2,4-bis(trifluoromethyl)benzenesulfonamide, 4-bromo-2-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide, 4-(2-furyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(5-fluoro-2-methoxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(5-methyl-2-thienyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-acetylphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-trifluoromethoxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3,4-dichlorophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3,4-methylenedioxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-pyridyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-acetylaminophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-thienyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(2-thienyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-carboxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methylsulfanylphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3,5-bis(trifluoromethyl)phenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-chlorophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-nitrophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(2-benzofuryl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(1-pyrrolidino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methyl-1-piperidino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(benzeneamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(benzylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(2-thienylmethylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-morpholinyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methyl-1-piperazinyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-pyridylmethylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4-dichloro-6-methyl-N-{5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}[1,1'-biphenyl]-4-sulfonamide, 2,4,6-trichloro-N-{5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-(4-{2-[(2R,6S)-2,6-dimethylmorpholinyl]-2-oxoethyl}-1,3-thiazol-2-yl)-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-(4-{2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-2-oxoethyl}-1,3-thiazol-2-yl)benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}[1,1'-biphenyl]-4-sulfonamide, N-{4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide, 2,4-dichloro-6-methyl-N-{4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4,6-trichloro-N-{4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-(1,1-dioxido-4-thiomorpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide, tert-butyl 4-[(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetyl]-1-piperazinecarboxylate, 4-acetyl-(4-[(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetyl])-1-piperazine, 4-[(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetyl]-1-piperazine trifluoroacetate, 3-chloro-2-methyl-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2-methyl-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-(trifluoromethoxy)benzenesulfonamide, 2,4-dichloro-6-methyl-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4-dichloro-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-(4-{2-[(2R)-2,4-dimethylpiperazinyl]-2-oxoethyl}-1,3-thiazol-2-yl)-methylbenzenesulfonamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-methoxy-N-methylacetamide, 3-chloro-2-methyl-N-[4-(2-oxopentyl)-1,3-thiazol-2-yl]benzenesulfonamide, 4-chloro-N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]benzenesulfonamide, 3-chloro-N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-ethoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-isopropoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, N-{4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-yl}-3-chloro-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-methoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-N-{4-[2-(2-fluoroethoxy)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(2,2,2-trifluoroethoxy)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(2-pyridinylsulfanyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(3-pyridinyloxy)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-(4-[2-methylsalicylethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl methanesulfonate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl acetate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl propionate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl 2-methylpropanoate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)ethyl 2-furoate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl benzoate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl 4-morpholinecarboxylate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino-1,3-thiazol-4-yl)ethyl diethylcarbamate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl ethylcarbamate, N-[4-(2-azidoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide, N-[4-(2-aminoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide hydrochloride, 4-chloro-N-{4-[2-(diethylamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 3-chloro-N-{4-[2-(diethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide hydrochloride, 3-chloro-N-{4-[2-(1-imidazolyl)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide hydrochloride, 3-chloro-2-methyl-N-{4-[2-(4-methyl-1-piperazinyl)ethyl]-1,3-thiazol-2-yl)benzenesulfonamide dihydrochloride, 3-chloro-2-methyl-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 3-chloro-2-methyl-N-{4-[(4-morpholinyl)methyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2,4,6-trichloro-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2,4-dichloro-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2,4-dichloro-6-methyl-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide hydrochloride, 3-chloro-N-{4-[2-(ethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 3-chloro-N-(4-{2-[(2-hydroxyethyl)amino]ethyl}-1,3-thiazol-2-yl)-2-methylbenzenesulfonamide, N-[2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl]-N-ethylacetamide, 3-chloro-2-methyl-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro=N-{4-[2-(2-hydroxy-3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 2,4-dichloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4-dichloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-6-methylbenzenesulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-2,4,6-trichlorobenzenesulfonamide, 4,5-dichloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-2-thienylsulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-4-phenoxybenzenesulfonamide, 3-fluoro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-5-(2-pyridyl)-2-thienylsulfonamide, 4-acetylamino-3-chloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[(3-oxo-4-morpholinyl)methyl]-1,3-thiazol-2-yl}-3-chloro-2-methylbenzenesulfonamide, N-{4-[3-(3-oxo-4-morpholinyl)propyl]-1,3-thiazol-2-yl}-3-chloro-2-methylbenzenesulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl},N-methyl-3-chloro-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(2-methyl-3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide, N-{4-[2-(acetylamino)ethyl]-1,3-thiazol-2-yl}-3-chloro-2-methyl-benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(4-(3-oxo-1,4-oxazepinyl))ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(1-pyrrolidonyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(1-(2-oxoimidazolinyl))ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(1-(2-oxooxazolinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-{4-[2-(N-(2-furylcarbonyl),N-2-hydroxyethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, hydrochloride, 3-chloro-2-methyl-N-{4-[2-(4-methyl-2-oxopiperazinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(methylsulfonylamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(N-methyl,N-methylsulfonamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(trifluoromethylsulfonylamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(N-methyl,N-trifluoromethylsulfonamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(4-(1-methylimidazolyl)sulfonylamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-{4-[2-(N-(3-chloro-2-methylphenylsulfonyl),N-methylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, N-[4-(2-bromoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-chloroethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-{4-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-1,3-thiazol-2-yl}benzenesulfonamide, and 3-chloro-N-{4-[2-(ethoxycarbonyl)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide.
4. The method according to any one of claims 1 to 3 for the treatment or prophylaxis of a medical condition involving delayed or impaired wound healing.
R1 is hydrogen or methyl;
X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen or methyl;
R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-morpholinolinylmethylene, ethoxycarbonyl, 5-methyl-1,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, 1,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexylmethyl, ethyl, 2-furylcarbonyl, 2-furylmethyl, hydrogen, 2-hydroxyethyl, 2-(1H-indol-3-yl)ethyl, isopropyl, methoxy, 2-methoxyethyl, methyl, 4-(1-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, propyl, trifluoromethylsulfonyl; or NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2-(3,4-dihydro-2(1H)isoquinolinyl), (2R,6S)-2,6-dimethylmorpholinyl, (2R)-2,4-dimethyl-1-piperazinyl, 2-hydroxy-3-oxomorpholinyl, imidazolyl, 2-methyl-3-oxomorpholinyl, 4-methyl-2-oxopiperazinyl, 4-methylpiperazinyl, morpholinyl, (1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomorpholinyl, 3-oxo-1,4-oxazepinyl, 2-oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomorpholinyl;
1,1-dioxido-thiomorpholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together morpholinyl;
R5O, wherein R5 is selected from acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, propionyl, 3-pyridinyl, and 2,2,2-trifluoroethyl.
3. The method according to any one of claims 1 or 2, wherein the compound is selected from:
ethyl (2-{[(2,4-dichloro-5-methylphenyl)sulfonyl]amino}1,3-thiazol-4-yl)acetate, ethyl 2-(2-[[(4-chlorophenyl)sulfonyl]amino]-1,3-thiazole-4-yl)acetate, ethyl 2-(2-{[(4-chloro-2,5-dimethylphenyl)sulfonyl]amino-1,3-thiazol-4-yl)acetate, ethyl 2-(2-{[(2,4-difluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-(2-(((4-methylphenyl)sulfonyl)amino)-1,3-thiazol-4-yl)acetate, ethyl 2-(2-{[(2,5-dichloro-3-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-{2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl 2-(2-{[(3-bromophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-nitrophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-nitrophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl {2-[(phenylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(4-isopropylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[3-({[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl] amino}carbonyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-({[4-({[4-(2-ethoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino}carbonyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[2-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-({[3-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-({[4-(trifluoromethyl)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl 2-(2-{[(4-bromophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-nitrophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,4-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(5-fluoro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-methoxy-4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3,5-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[4-(3-chloro-2-cyanophenoxy)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(3,4-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-butoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[4-(acetylamino)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl {2-[(8-quinolinylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(3,4-dimethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-iodophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(3-chloro-4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[5-(dimethylamino)-1-naphthyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(5-bromo-2-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,5-dimethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl {2-[(2-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl {2-[(mesitylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(3-bromo-5-chloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl {2-[({5-[(benzoylamino)methyl]-2-thienyl}sulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl {2-[({5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl}sulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(4-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl{2-[({5-[2-(methylsulfanyl)-4-pyrimidinyl]-2-thienyl}sulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(3-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2,4,5-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[(E)-2-phenylethenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,3,4-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-2,5-difluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl]acetate, ethyl [2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,3-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-bromophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4,5-dichloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl [2-({[4-(phenylsulfonyl)-2-thienyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl [2-({[5-(phenylsulfonyl)-2-thienyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(2,6-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-cyanophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-({[4-(acetylamino)-3-chlorophenyl]sulfonyl}amino)-1,3-thiazol-4-yl]acetate, ethyl (2-{[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]amino}-1,3-thiazol-yl)acetate, ethyl (2-{[(3-methoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-5-chloro-2-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetate, ethyl (2-{[(2,5-dichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-methanesulfonylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-methanesulfonylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-2-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-methyl-4-trifluoromethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4 yl)acetate, ethyl (2-{[(2,3,4-trifluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2{[(4-chloro-2,3,1-benzoxadiazolyl)sulfonyl]amino}-1,3-thiazol-4 yl)acetate, ethyl (2-{[(2,4,6-trifluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(5-carboxy-4-chloro-2-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-(5-chlorothienyl))sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-chloro-4-fluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(2-(5-(3-isoxazolo)thienyl))sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-{[(4-bromo-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ZZZZ ethyl (2-{[(4-phenoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(4-chloro-2,6-dimethylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(2-methyl-4-trifluoromethoxyphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2-~[(2,4-bis(trifluoromethyl)phenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl 2- {2-[ [(3-chloro-2-methylphenyl)sulfonyl] (methyl)amino]-1,3-thiazol-4-yl} acetate, ethyl oxo(2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl (2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1;3-thiazol-4-. yl)(oxo)acetate, , ethyl oxo(2-~[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, ethyl ~2-[([l,l'~ biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}(oxo)acetate, ethyl (2-~[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)(oxo)acetate, 2-(2-~[(4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, 2-(2- f [(2,5-dichloro-3-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, (2-{[(2-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetic acid, isopropyl 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, phenyl 2-(2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl (2- f [(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl ~2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-5-methyl-1,3-thiazol-4-y1 } acetate, methyl (2-~[(4-chlorophenyl)sulfonyl]amino}-5-methyl-1,3-thiazol-4-yl)acetate, methyl (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-5-methyl-1,3-thiazol-4-yl)acetate, methyl [2-({[4-(3-chloro-2-cyanophenoxy)phenyl]sulfonyl}amino)-5-methyl-1,3-thiazol-4-yl] acetate, methyl (5-methyl-2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl (5-methyl-2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate, methyl (2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-5-methyl-1,3-thiazol-4-yl)acetate, N-(2-methoxyethyl)-2-(2-{[(4-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(2,5-dichloro-3-thienyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-methylacetamide, N-(1,3-benzodioxol-5-ylmethyl)-2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, N-(2-furylmethyl)-2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, 2-(2-{[(2,4-difluorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethylacetamide, N-isopropyl-2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, N-[2-(1H-indol-3-yl)ethyl]-2-{2-[(1-naphthylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, N-(cyclohexylmethyl)-2-{2-[(phenylsulfonyl)amino]-1,3-thiazol-4-yl}acetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-methylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-phenylacetamide, 2-(2-{[(4-chlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-(2-furylmethyl)acetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-diethylacetamide, 2-{2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N,N-diethylacetamide, N,N-diethyl-2-(2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-diethylacetamide, N,N-diethyl-2-(2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-{2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N,N-diisopropylacetamide, N,N-diisopropyl-2-(2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-diisopropylacetamide, N,N-diisopropyl-2-(2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-diisopropylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-dipropylacetamide, N-benzyl-2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N,N-dimethylacetamide, 3-chloro-N-{4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-methyl-N-phenylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-isopropyl-N-methylacetamide, 2-{2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N-isopropyl-N-methylacetamide, N-ethyl-N-methyl-2-(2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-(2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethyl-N-methylacetamide, N-ethyl-N-methyl-2-(2-{[(4-propylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetamide, 2-{2-[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,3-thiazol-4-yl}-N-ethyl-N-methylacetamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-ethyl-N-methylacetamide, 3-chloro-2-methyl-N-{4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}[1,1'-biphenyl]-4-sulfonamide, N-{4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide;
2,4-dichloro-6-methyl-N-{4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4,6-trichloro-N-{4-[2-oxo-2-(1-piperidinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4,6-trichloro-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4-dichloro-6-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}[1,1'-biphenyl]-4-sulfonamide, N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide, 2,4-dichloro-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-chloro-2,6-dimethyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide, N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-phenoxybenzenesulfonamide, 2-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-(trifluoromethoxy)benzenesulfonamide, N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-2,4-bis(trifluoromethyl)benzenesulfonamide, 4-bromo-2-methyl-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide, 4-(2-furyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(5-fluoro-2-methoxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(5-methyl-2-thienyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-acetylphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-trifluoromethoxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3,4-dichlorophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3,4-methylenedioxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-pyridyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-acetylaminophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-thienyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(2-thienyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-carboxyphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methylsulfanylphenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3,5-bis(trifluoromethyl)phenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-chlorophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-nitrophenyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(2-benzofuryl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(1-pyrrolidino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methyl-1-piperidino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(benzeneamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(benzylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(2-thienylmethylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-morpholinyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(4-methyl-1-piperazinyl)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 4-(3-pyridylmethylamino)-N-{4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4-dichloro-6-methyl-N-{5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}[1,1'-biphenyl]-4-sulfonamide, 2,4,6-trichloro-N-{5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{5-methyl-4-[2-(4-morpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-(4-{2-[(2R,6S)-2,6-dimethylmorpholinyl]-2-oxoethyl}-1,3-thiazol-2-yl)-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-(4-{2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]-2-oxoethyl}-1,3-thiazol-2-yl)benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}[1,1'-biphenyl]-4-sulfonamide, N-{4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide, 2,4-dichloro-6-methyl-N-{4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4,6-trichloro-N-{4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-(1,1-dioxido-4-thiomorpholinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide, tert-butyl 4-[(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetyl]-1-piperazinecarboxylate, 4-acetyl-(4-[(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetyl])-1-piperazine, 4-[(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetyl]-1-piperazine trifluoroacetate, 3-chloro-2-methyl-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2-methyl-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}-4-(trifluoromethoxy)benzenesulfonamide, 2,4-dichloro-6-methyl-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4-dichloro-N-{4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-(4-{2-[(2R)-2,4-dimethylpiperazinyl]-2-oxoethyl}-1,3-thiazol-2-yl)-methylbenzenesulfonamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)-N-methoxy-N-methylacetamide, 3-chloro-2-methyl-N-[4-(2-oxopentyl)-1,3-thiazol-2-yl]benzenesulfonamide, 4-chloro-N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]benzenesulfonamide, 3-chloro-N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-ethoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-isopropoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, N-{4-[2-(benzyloxy)ethyl]-1,3-thiazol-2-yl}-3-chloro-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-methoxyethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-N-{4-[2-(2-fluoroethoxy)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(2,2,2-trifluoroethoxy)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(2-pyridinylsulfanyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(3-pyridinyloxy)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-(4-[2-methylsalicylethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl methanesulfonate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl acetate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl propionate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl 2-methylpropanoate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino]-1,3-thiazol-4-yl)ethyl 2-furoate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl benzoate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl 4-morpholinecarboxylate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino-1,3-thiazol-4-yl)ethyl diethylcarbamate, 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl ethylcarbamate, N-[4-(2-azidoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide, N-[4-(2-aminoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide hydrochloride, 4-chloro-N-{4-[2-(diethylamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 3-chloro-N-{4-[2-(diethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide hydrochloride, 3-chloro-N-{4-[2-(1-imidazolyl)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide hydrochloride, 3-chloro-2-methyl-N-{4-[2-(4-methyl-1-piperazinyl)ethyl]-1,3-thiazol-2-yl)benzenesulfonamide dihydrochloride, 3-chloro-2-methyl-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 3-chloro-2-methyl-N-{4-[(4-morpholinyl)methyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2,4,6-trichloro-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2,4-dichloro-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, 2,4-dichloro-6-methyl-N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide hydrochloride, N-{4-[2-(4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-4-propylbenzenesulfonamide hydrochloride, 3-chloro-N-{4-[2-(ethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 3-chloro-N-(4-{2-[(2-hydroxyethyl)amino]ethyl}-1,3-thiazol-2-yl)-2-methylbenzenesulfonamide, N-[2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)ethyl]-N-ethylacetamide, 3-chloro-2-methyl-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro=N-{4-[2-(2-hydroxy-3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, 2,4-dichloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 2,4-dichloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-6-methylbenzenesulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-2,4,6-trichlorobenzenesulfonamide, 4,5-dichloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-2-thienylsulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-4-phenoxybenzenesulfonamide, 3-fluoro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}-5-(2-pyridyl)-2-thienylsulfonamide, 4-acetylamino-3-chloro-N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, N-{4-[(3-oxo-4-morpholinyl)methyl]-1,3-thiazol-2-yl}-3-chloro-2-methylbenzenesulfonamide, N-{4-[3-(3-oxo-4-morpholinyl)propyl]-1,3-thiazol-2-yl}-3-chloro-2-methylbenzenesulfonamide, N-{4-[2-(3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl},N-methyl-3-chloro-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(2-methyl-3-oxo-4-morpholinyl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide, N-{4-[2-(acetylamino)ethyl]-1,3-thiazol-2-yl}-3-chloro-2-methyl-benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(4-(3-oxo-1,4-oxazepinyl))ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(1-pyrrolidonyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(1-(2-oxoimidazolinyl))ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(1-(2-oxooxazolinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-{4-[2-(N-(2-furylcarbonyl),N-2-hydroxyethylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, hydrochloride, 3-chloro-2-methyl-N-{4-[2-(4-methyl-2-oxopiperazinyl)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(methylsulfonylamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(N-methyl,N-methylsulfonamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(trifluoromethylsulfonylamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(N-methyl,N-trifluoromethylsulfonamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-2-methyl-N-{4-[2-(4-(1-methylimidazolyl)sulfonylamino)ethyl]-1,3-thiazol-2-yl}benzenesulfonamide, 3-chloro-N-{4-[2-(N-(3-chloro-2-methylphenylsulfonyl),N-methylamino)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide, N-[4-(2-bromoethyl)-1,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide, 3-chloro-N-[4-(2-chloroethyl)-1,3-thiazol-2-yl]-2-methylbenzenesulfonamide, 3-chloro-2-methyl-N-{4-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-1,3-thiazol-2-yl}benzenesulfonamide, and 3-chloro-N-{4-[2-(ethoxycarbonyl)ethyl]-1,3-thiazol-2-yl}-2-methylbenzenesulfonamide.
4. The method according to any one of claims 1 to 3 for the treatment or prophylaxis of a medical condition involving delayed or impaired wound healing.
5. The method according to claim 4 wherein the medical condition involving delayed or impaired wound healing is diabetes.
6. The method according to claim 4 wherein the medical condition involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
7. The method according to any one of claims 1 to 3 for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
8. Use of a compound as defined in any one of claims 1 to 3 in the manufacture of a medicament for promoting wound healing, said compound being an inhibitor of 11-.beta.-hydroxysteroid dehydrogenase type 1.
9. The use according to claim 8 in the manufacture of a medicament for the treatment of prophylaxis of a medical condition involving delayed or impaired wound healing.
10. The use according to claim 9 wherein the medical condition involving delayed or impaired wound healing is diabetes.
11. The use according to claim 9 wherein the medical condition involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
12. The use according to claim 8 in the manufacture of a medicament for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0301882A SE0301882D0 (en) | 2003-06-25 | 2003-06-25 | New use I |
| SE0301882-7 | 2003-06-25 | ||
| PCT/SE2004/000996 WO2004112784A1 (en) | 2003-06-25 | 2004-06-21 | New use i |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2529406A1 true CA2529406A1 (en) | 2004-12-29 |
Family
ID=27656617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002529406A Abandoned CA2529406A1 (en) | 2003-06-25 | 2004-06-21 | New use i |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1638553A1 (en) |
| JP (1) | JP2007521264A (en) |
| KR (1) | KR20060023570A (en) |
| CN (1) | CN1812784A (en) |
| AU (1) | AU2004249099A1 (en) |
| CA (1) | CA2529406A1 (en) |
| NO (1) | NO20060416L (en) |
| SE (1) | SE0301882D0 (en) |
| WO (1) | WO2004112784A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4789934B2 (en) | 2004-05-24 | 2011-10-12 | アムジエン・インコーポレーテツド | Inhibitors of type 1 11-beta-hydroxysteroid dehydrogenase |
| US8686011B2 (en) | 2004-05-24 | 2014-04-01 | Amgen Inc. | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
| GB0506133D0 (en) * | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
| JP5140577B2 (en) | 2005-03-31 | 2013-02-06 | タケダ カリフォルニア インコーポレイテッド | Hydroxysteroid dehydrogenase inhibitor |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| WO2007061661A2 (en) | 2005-11-22 | 2007-05-31 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| JP2010500300A (en) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for their preparation, agents containing these compounds, and uses thereof |
| JP5098011B2 (en) * | 2006-11-20 | 2012-12-12 | 国立大学法人山口大学 | Wound healing promoter |
| DE102007005045B4 (en) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazine derivatives, process for their preparation and their use as medicines |
| ES2523196T3 (en) * | 2007-07-13 | 2014-11-21 | Icagen, Inc. | Sodium Channel Inhibitors |
| EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| KR20120060207A (en) | 2009-08-26 | 2012-06-11 | 사노피 | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
| WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2012120051A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
| EP2683701B1 (en) | 2011-03-08 | 2014-12-24 | Sanofi | Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use |
| EP2766349B1 (en) | 2011-03-08 | 2016-06-01 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120056A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683702B1 (en) | 2011-03-08 | 2014-12-24 | Sanofi | New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application |
| WO2012120057A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN103204824B (en) * | 2012-01-12 | 2015-04-08 | 清华大学深圳研究生院 | 2-aminothiazole-4-amide derivative, its preparation method and application |
| TW201512171A (en) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | Chemical compounds |
| CN105061288B (en) * | 2015-08-07 | 2017-09-15 | 武汉华素康生物科技有限公司 | Compound and its preparation method and application |
| EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
| CN118340765B (en) * | 2024-04-30 | 2024-08-23 | 广州市朝利良生物科技有限公司 | Application of benzamide compound in preparation of wound healing promoting medicine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH10639A (en) * | 1967-07-17 | 1977-07-22 | Research Corp | Method of treatment and composition containing silver sulfadiazine |
| NZ306734A (en) * | 1995-04-04 | 2000-01-28 | Texas Biotechnology Corp | |
| JP2001503037A (en) * | 1996-10-16 | 2001-03-06 | アメリカン・サイアナミド・カンパニー | Preparation and use of ortho-sulfonamidoheteroarylhydroxamic acids as inhibitors of matrix metalloproteinases and tace |
| SE0001899D0 (en) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
-
2003
- 2003-06-25 SE SE0301882A patent/SE0301882D0/en unknown
-
2004
- 2004-06-21 EP EP04749034A patent/EP1638553A1/en not_active Withdrawn
- 2004-06-21 KR KR1020057024626A patent/KR20060023570A/en not_active Withdrawn
- 2004-06-21 WO PCT/SE2004/000996 patent/WO2004112784A1/en not_active Ceased
- 2004-06-21 CA CA002529406A patent/CA2529406A1/en not_active Abandoned
- 2004-06-21 AU AU2004249099A patent/AU2004249099A1/en not_active Abandoned
- 2004-06-21 JP JP2006517048A patent/JP2007521264A/en active Pending
- 2004-06-21 CN CNA2004800177434A patent/CN1812784A/en active Pending
-
2006
- 2006-01-25 NO NO20060416A patent/NO20060416L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004112784A1 (en) | 2004-12-29 |
| NO20060416L (en) | 2006-03-24 |
| JP2007521264A (en) | 2007-08-02 |
| KR20060023570A (en) | 2006-03-14 |
| AU2004249099A1 (en) | 2004-12-29 |
| SE0301882D0 (en) | 2003-06-25 |
| EP1638553A1 (en) | 2006-03-29 |
| CN1812784A (en) | 2006-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2529406A1 (en) | New use i | |
| WO2004112782A1 (en) | New use v | |
| WO2004113310A1 (en) | Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing | |
| WO2004112779A1 (en) | New use vii | |
| US20070066614A1 (en) | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| JP2018048190A (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
| CA2915566C (en) | 2,3-dihydrobenzofuran-5-yl compounds as dyrk kinase inhibitors | |
| CA2466490A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| CA2718383A1 (en) | Heteroaryl-substituted dicyanopyridines and use thereof for treatment of cardiovascular diseases | |
| NZ229266A (en) | Compositions containing arylmethylene-substituted thiazolidinone, imidazolidinone and oxazolidinone derivatives and sulphur analogues (thiones) | |
| EP1223932A1 (en) | Compounds and methods | |
| JPWO2009054439A1 (en) | PAI-1 production inhibitor | |
| JP2010248205A (en) | Benzazole derivative for treating scleroderma | |
| KR20100096094A (en) | Pharmaceutical composition for treatment of cataract | |
| US7173030B2 (en) | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | |
| WO2004112783A1 (en) | New use iv | |
| WO2004112781A1 (en) | New use ii | |
| ZA200401305B (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1. | |
| WO2004112785A1 (en) | New use iii | |
| ZA200209769B (en) | 2-aminothiazoline derivatives and their use as no-synthase inhibitors. | |
| JP2003531145A (en) | 1- (1H-1,2,4-triazol-1-yl) butan-2-ol derivative | |
| WO1997018811A1 (en) | A method of treating myotonic dystrophy | |
| JPH02167224A (en) | Antilipemic agent | |
| ZA200401311B (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1. | |
| HK1092729A (en) | New use i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |